News and publications

Biotest Press releases

483 Press releases
Filter:
29.02.2024

Biotest achieves EBIT forecast for 2023

29.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2024 CORPORATE
28.02.2024

Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care

28.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2024 CORPORATE
14.02.2024

Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate

14.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2024 CORPORATE
30.01.2024

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

30.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2024 AFR
22.01.2024

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

22.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2024 AFR
18.01.2024

Biotest AG opens 11th plasma collection centre in Germany

18.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2024 CORPORATE
11.01.2024

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

11.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2024 AFR
12.12.2023

Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)

12.12.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
28.11.2023

Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation

28.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
02.11.2023

Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023

02.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
05.10.2023

Biotest AG: Peter Janssen appointed new Chairman of the Board of Biotest AG

Announcement according to Article 17 European Market Abuse Regulation (MAR)  Peter Janssen appointed new Chairman of the Board of Biotest AG Dreieich, 5 October 2023. In its meeting today, the Supervisory Board of Biotest AG appointed Mr. Peter Janssen (57) as Chairman of the Management Board of Biotest AG with effect from 1 January 2024. He ...

Further information
2023 ADHOC
05.10.2023

Biotest AG: Increase of the EBIT guidance

Announcement according to Article 17 European Market Abuse Regulation (MAR)  Increase of the EBIT guidance Dreieich, 05 October 2023. Against the background of the agreements concluded between Biotest AG, Dreieich, Germany and Grifols, S.A., Barcelona, Spain, which include a technology transfer and licensing agreement, the Management Board of ...

Further information
2023 ADHOC
21.09.2023

Biotest AG: Biotest receives approval for innovative immunoglobulin Yimmugo® in the UK

21.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
12.09.2023

Biotest AG: Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin

12.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
07.09.2023

Biotest AG: US Food and Drug Administration FDA accepts marketing authorization application for immunoglobulin Yimmugo

07.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
05.09.2023

Biotest AG: Biotest treats first shingles patient with Varitect® CP in VARIZOSTA study

05.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
04.09.2023

Biotest AG: Biotest Supervisory Board extends Management Board contract of Dr Jörg Schüttrumpf by 5 years

04.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
10.08.2023

Biotest AG: Biotest increases EBIT to Euro 19.8 million in the first half of 2023

10.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
27.07.2023

Biotest AG: Biotest increases EBIT to Euro 19.8 million

27.07.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
01.06.2023

Biotest AG: Biotest presents gigantic artwork to visualize its sustainability initiatives

01.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
09.05.2023

Biotest AG: Annual General Meeting of Biotest AG elects Raimon Grifols Roura to the Supervisory Board

09.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
04.05.2023

Biotest AG: Biotest’s Hyperimmunoglobulin Cytotect® CP receives five additional Marketing Authorisations in Europe

04.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
28.04.2023

Biotest AG: Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised

Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)   Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised  Dreieich, 28 April 2023. The Supervisory Board approved the signing and execution of several agreements by the Board of Management to further strengthen the cooperation between ...

Further information
2023 ADHOC
25.04.2023

Biotest AG: Biotest AG opens 12th plasma collection centre in Hungary

25.04.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
20.04.2023

Biotest AG: Biotest AG opens 10th plasma collection centre in Germany

20.04.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
30.03.2023

Biotest AG: Biotest achieves important milestone in phase III trial in acquired fibrinogen deficiency

30.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
23.03.2023

Biotest AG: Biotest core business profitable at Euro 60.7 million

23.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
14.03.2023

Biotest AG: Biotest donates human albumin for earthquake victims in Turkey

14.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
28.02.2023

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

28.02.2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 AFR
28.02.2023

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

28.02.2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 AFR
10.02.2023

Biotest AG: Biotest Supervisory Board appoints new Management Board member

10.02.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
09.02.2023

Biotest AG: Biotest significantly exceeds EBIT guidance 2022

Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)   Biotest significantly exceeds EBIT guidance 2022 Dreieich, 09 February 2023. According to preliminary and not yet audited figures, the Biotest Group slightly increased its revenues to € 516.1 million in the financial year 2022, compared to € 515.6 million in the ...

Further information
2023 ADHOC
24.01.2023

Biotest AG: First patient treated with Cytotect® CP Biotest in study after heart and lung transplantation

24.01.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
19.01.2023

Biotest AG: Biotest receives 'Innovation Champion of Sustainability' award

19.01.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
10.01.2023

Biotest AG: Biotest treats first COVID-19 patients with trimodulin in TRICOVID phase III trial

10.01.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2023 CORPORATE
08.12.2022

Biotest AG: First patient enrolled in phase II clinical trial for treatment of chronic hepatitis B with hyperimmunoglobulins

08.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
14.11.2022

Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022

14.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
14.11.2022

Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation)

14.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
08.11.2022

Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022

08.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
13.10.2022

Biotest AG: Biotest AG opens 14th plasma collection centre in the Czech Republic

13.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
26.09.2022

Biotest AG: Biotest AG opens 13th plasma collection centre in the Czech Republic

26.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
06.09.2022

Biotest AG: Biotest AG opens 12th plasma collection centre in the Czech Republic

06.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
11.08.2022

Biotest AG: Biotest achieves an improved adjusted EBIT by 9.8% of EUR 32.4 million in the first half of 2022

11.08.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
28.07.2022

Biotest AG: Biotest increases EBITDA in first half-year by 52% to 8.8 million EUR

28.07.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
25.07.2022

Biotest AG: Biotest grants Renate & Hans Schleussner Research Award for the first time

25.07.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
10.06.2022

Biotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency

10.06.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
09.06.2022

Biotest AG: Biotest AG opens 11th plasma collection centre in Czech Republic

09.06.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
24.05.2022

Biotest AG: Biotest AG opens 10th plasma collection centre in Czech Republic

24.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
06.05.2022

Biotest AG: Dr Bernhard Ehmer new Chairman of the Supervisory Board of Biotest AG

06.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
05.05.2022

Biotest AG: Biotest records sales of 115 million euros in the first quarter of 2022

05.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
05.05.2022

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

05.05.2022 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 AFR
05.05.2022

Biotest AG: Annual General Meeting approves dividend distribution

05.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
02.05.2022

Biotest AG: Biotest Supervisory Board appoints new Management Board member

02.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
29.04.2022

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

29.04.2022 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 PVR
29.04.2022

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

29.04.2022 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 PVR
27.04.2022

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

27.04.2022 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 PVR
27.04.2022

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

27.04.2022 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 PVR
25.04.2022

Biotest AG: Grifols acquires majority of voting rights in Biotest

25.04.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
07.04.2022

Biotest AG: Biotest submits marketing authorisation application for IgG Next Generation and signed first licensing agreement

07.04.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
24.03.2022

Biotest AG: Biotest exceeds sales guidance in fiscal year 2021

24.03.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
10.03.2022

Biotest AG: Biotest AG opens ninth plasma collection centre in Czech Republic

10.03.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
16.02.2022

Biotest AG: Biotest exceeds Revenue guidance 2021

Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest exceeds Revenue guidance 2021Dreieich, 16 February 2022. According to preliminary and not yet audited figures, Biotest AG increased its revenues by more than 6.5 % to € 515.6 million in fiscal year 2021, compared to € 484.2 million in the previous year. The increase in sales, which is above the ...

Further information
2022 ADHOC
18.01.2022

Biotest AG: Biotest combats climate change through CO2-neutral production

18.01.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
12.01.2022

Biotest AG: Biotest AG opens eighth plasma collection centre in Czech Republic

12.01.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 CORPORATE
10.01.2022

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

10.01.2022 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2022 PVR
07.01.2022

Biotest AG: Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer

Announcement according to Article 17 European Market Abuse Regulation (MAR)Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offerDreieich, 7 January 2022. In accordance with Sections 23 para. 1 sentence 1 no. 2, no. 4 of the German Securities Acquisition and Takeover Act (WpÜG), Grifiols, S.A. has today published on its website at ...

Further information
2022 ADHOC
14.12.2021

Biotest AG: Biotest treats first CMV-positive pregnant woman in Phase III clinical trial to prevent transmission of CMV infection to the unborn child

14.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2021 CORPORATE
09.12.2021

Biotest AG: Biotest Supervisory Board appoints new Management Board member

09.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2021 CORPORATE
08.12.2021

Biotest AG: Biotest adjusts guidance

08.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2021 CORPORATE
08.12.2021

Biotest AG: Reduction of guidance

Announcement according to Article 17 European Market Abuse Regulation (MAR)Dreieich, 08 Dezember 2021. Due to the changing market environment for the plasmatic coagulation factor VIII, the Supervisory Board of Biotest Aktiengesellschaft decided in its meeting today that Biotest will only produce factor VIII in a sales-correlated manner in the future. Biotest will therefore make ...

Further information
2021 ADHOC
30.11.2021

Biotest AG: Biotest receives approval for Intratect(R) in France

30.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2021 CORPORATE
25.11.2021

Biotest AG: Biotest AG opens seventh plasma collection centre in Czech Republic

25.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2021 CORPORATE
23.11.2021

Biotest AG: Biotest accelerates trimodulin development in hospitalized COVID-19 patients with federal funding in the volume of 29 million EUR

23.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2021 CORPORATE
16.11.2021

Biotest AG: Cytotect CP(R) Biotest activates immune cells that are crucial to control Cytomegalovirus

16.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2021 CORPORATE
11.11.2021

Biotest AG: Biotest increases sales by 9% in the first nine months 2021

11.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2021 CORPORATE
05.11.2021

Biotest AG: Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.

05.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ...

Further information
2021 CORPORATE
11.10.2021

Biotest AG: Biotest identifies a benefit with trimodulin in a relevant subgroup of hospitalised COVID-19 patients

11.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
20.09.2021

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

20.09.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 PVR
17.09.2021

Biotest AG: Takeover Offer: Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AG

Announcement according to Article 17 European Market Abuse Regulation (MAR)Takeover Offer: Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AGDreieich, 17 September 2021. Grifols S.A. announced today its decision to make a voluntary public takeover offer for all out-standing ordinary and preference shares of Biotest AG for €43.00 per ordinary share ...

Further information
2021 ADHOC
15.09.2021

Biotest AG: Biotest announces the new Renate & Hans Schleussner Award for scientific research

15.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
26.08.2021

Biotest AG: Biotest receives approval for phase III clinical trial in pregnant women for prevention of CMV infection of the unborn baby

26.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
23.08.2021

Biotest AG: Biotest AG opens sixth plasma collection centre in Czech Republic

23.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
13.08.2021

Biotest AG: Trimodulin does not reach the primary endpoint in the phase II trial in patients with severe COVID-19

13.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
12.08.2021

Biotest AG: Biotest increases sales by 10% in the first half of 2021

12.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
03.08.2021

Biotest AG: Biotest proves the mode of action of trimodulin for the treatment of COVID-19

03.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
20.07.2021

Biotest AG: Biotest AG opens 11th plasma collection centre in Hungary

20.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
13.07.2021

Biotest AG: Biotest receives manufacturing license for new production facility and plans to hire 150 additional employees

13.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
06.07.2021

Biotest AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

06.07.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 AFR
06.07.2021

Biotest AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

06.07.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 AFR
06.07.2021

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

06.07.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 AFR
06.07.2021

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

06.07.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 AFR
06.07.2021

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

06.07.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 AFR
06.07.2021

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

06.07.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 AFR
06.07.2021

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

06.07.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 AFR
30.06.2021

Biotest AG: Biotest AG opens fifth plasma collection centre in Czech Republic

30.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
02.06.2021

Biotest AG: Biotest successfully completes recruitment for its clinical trial with trimodulin in severe COVID-19 patients

02.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
01.06.2021

Biotest AG: Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR)

Announcement according to Article 17 European Market Abuse Regulation (MAR)Dreieich, 1 June 2021. Biotest confirms it has been informed by its major shareholder Tiancheng International Investment Limited ("TII") that TII is considering strategic options with regard to its stake in Biotest. Those deliberations are in early stages and may or may not result in a transaction. At this ...

Further information
2021 ADHOC
11.05.2021

Biotest AG: Biotest increases sales by more than 22 % in the first quarter of 2021 to 120 million EUR

11.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
11.05.2021

Correction of a release from 11/05/2021, 14:30 CET/CEST - Biotest AG: Annual General Meeting approves dividend distribution

11.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
11.05.2021

Biotest AG: Annual General Meeting approves dividend distribution

11.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
06.05.2021

Biotest AG: Biotest AG opens 10th plasma collection centre in Hungary

06.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
22.04.2021

Biotest AG: Biotest confirms good tolerability and efficacy of Intratect(R) in primary and secondary immunodeficiencies in an observational study

22.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
07.04.2021

Biotest AG: Biotest accelerates fibrinogen phase III study with additional patient group

07.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
31.03.2021

Biotest AG: Biotest exceeds Sales and EBIT forecast in the 2020 financial year

31.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
23.02.2021

Biotest AG: Biotest supports clinical study with Pentaglobin(R) in COVID-19 at the University Hospital AKH Vienna

23.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
18.02.2021

Biotest AG: Biotest is the first plasma protein manufacturer in Germany to produce an investigational hyperimmunoglobulin preparation against COVID-19 and can provide further production capacities

18.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 CORPORATE
11.02.2021

Biotest AG: Biotest significantly exceeds Revenue and EBIT guidance

Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest significantly exceeds Revenue and EBIT guidanceDreieich, 11 February 2021. According to preliminary and not yet audited figures, Biotest AG increased its revenues by more than 15% to € 484 million in fiscal year 2020, compared to € 419 million in the previous year. The increase in revenues primarily ...

Further information
2021 ADHOC
01.02.2021

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

01.02.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 PVR
11.01.2021

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

11.01.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2021 PVR
26.11.2020

Biotest AG: Biotests Pentaglobin(R) is a treatment option for COVID-19 patients additionally affected by bacterial infections

26.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
12.11.2020

Biotest AG: Biotest increases adjusted 9-month EBIT by over 21% to € 52 million

12.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
06.10.2020

Biotest AG: Biotest treats first COVID-19 patient with trimodulin

06.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
04.10.2020

Biotest AG:

04.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
10.09.2020

Biotest AG: Biotest is one of the first plasma protein manufacturers to provide digital package leaflets for all products

10.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
03.09.2020

Biotest AG: Biotest phase II study for the treatment of severe COVID-19 patients with trimodulin approved

03.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
01.09.2020

Biotest AG: Biotest achieves another important clinical milestone for IgG Next Generation

01.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
13.08.2020

Biotest AG: Biotest increases sales in the first half of 2020 by over 20% to € 234.8 million

13.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
21.07.2020

Biotest AG: Biotest presented promising data on next generation recombinant Factor VIII at ISTH 2020

21.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
20.07.2020

Biotest AG: Biotest Supervisory Board extends contracts with the Board of Management

20.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
16.07.2020

Biotest AG: Biotest submits phase II study with trimodulin for the treatment of severe COVID-19 patients

16.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
09.07.2020

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

09.07.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 AFR
09.07.2020

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

09.07.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 AFR
10.06.2020

Biotest AG: Biotest successfully enters China, the world's biggest Human Albumin market

10.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
08.06.2020

Biotest AG: Biotest's Zutectra(R) demonstrates improved quality of life in a study with liver transplant patients

08.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
26.05.2020

Biotest AG: Biotest achieves significant milestone by completing phase I/III clinical trial with fibrinogen

26.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
08.05.2020
2020 CORPORATE
08.05.2020

Biotest AG: Annual General Meeting approves dividend distribution

08.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
06.04.2020

Biotest AG: Biotest produces life-saving medicine derived from plasma from healed COVID-19 patients and participates in a cross-industry initiative

06.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
03.04.2020

Biotest AG: Biotest is developing with Trimodulin a COVID-19 therapy for patients with a severe course of the disease

03.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
30.03.2020

Biotest AG: Biotest exceeds EBIT forecast in the 2019 financial year

30.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
02.03.2020

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

02.03.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 PVR
26.02.2020

Biotest AG: Biotest exceeds already raised EBIT guidance

Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest exceeds already raised EBIT guidanceDreieich, 26 February 2020. According to preliminary and unaudited figures, the Biotest AG generated in the 2019 financial year revenue of € 419.1 million (+4.7%) compared to € 400.3 million in the previous year.EBIT amounted to € -1.2 million in the 2019 ...

Further information
2020 ADHOC
25.02.2020

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

25.02.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 PVR
15.01.2020

Biotest AG: Biotest's CMV-specific hyperimmunoglobulin Cytotect CP Biotest receives UK marketing authorisation

15.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2020 CORPORATE
17.12.2019

Biotest AG: Biotest hosts first international symposium to increase awareness for cytomegalovirus infections

17.12.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2019 CORPORATE
11.12.2019

Biotest AG: Biotest AG opens fourth plasma collection centre in Czech Republic

11.12.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2019 CORPORATE
04.12.2019

Biotest AG: Biotest AG increases Guidance

Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest AG increases GuidanceDreieich, 4 December 2019. Following the evaluation of the current business situation, the Management Board today confirms the revenue guidance for the 2019 financial year in the range of € 420 - 430 million. Although the efforts to find a co-marketing and co-development partner ...

Further information
2019 ADHOC
18.11.2019

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

18.11.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2019 PVR
14.11.2019

Biotest AG: Biotest increases sales by 1.8% to EUR 294.9 million

14.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at ...

Further information
2019 CORPORATE
29.10.2019

Biotest AG: Biotest shows excellent efficacy and tolerability of Haemoctin(R) SDH in long-term study of patients with haemophilia A

Biotest shows excellent efficacy and tolerability of Haemoctin(R) SDH in long-term study of patients with haemophilia A - Clinical data of the worldwide longest surveillance study on198 patients representing all age groups (0-88 years) published- Patients benefit more from prophylactic than from on-demand therapy- Previously untreated haemophilia A patients scarcely develop ...

Further information
2019 CORPORATE
05.09.2019

Biotest AG: Biotest Achieves Important Clinical Milestone for IgG Next Generation

Biotest Achieves Important Clinical Milestone for IgG Next Generation- Phase III study in Primary Immune Thrombocytopenia (ITP) completed, data evaluation in progress, promising results - The study is one of two pivotal phase III studies in the clinical program for IgG Next Generation, a novel development of our polyvalent immunoglobulin G- Clinical development in line with ...

Further information
2019 CORPORATE
14.08.2019

Biotest AG: Biotest increases adjusted EBIT by 12% to EUR 29.9 million

Biotest increases adjusted EBIT by 12% to EUR 29.9 million- Earnings after taxes reaches EUR 2.0 million- Expansion project Biotest Next Level proceeding according to plan- Long-term financing of the Biotest GroupDreieich, 14 August 2019. In the first half of the 2019 financial year, the Biotest Group recorded sales revenues of EUR 195.1 million (same period of the previous year: ...

Further information
2019 CORPORATE
07.05.2019

Biotest AG: Biotest reaches revenues of EUR 77.5 million in the first quarter 2019

Biotest reaches revenues of EUR 77.5 million in the first quarter 2019 - Guidance confirmed- Earnings after taxes in the first quarter totalled to EUR -1.2 million Dreieich, 7 May 2019. In the first quarter of 2019, the Biotest Group reported revenue of EUR 77.5 million. This is a decrease of 11.9 % over the EUR 88.0 million in sales during the same period of the previous year.EBIT ...

Further information
2019 CORPORATE
07.05.2019

Biotest AG: Annual general meeting approves payout of dividend

Biotest AG: Annual general meeting approves payout of dividend- Dividend payout of EUR 0.04 per preference shareDreieich/ Frankfurt a. M., 07 May 2019. At the annual general meeting (AGM) held on 07 May 2019 in Frankfurt/ Main, shareholders of Biotest AG approved the payment of a dividend. With 97.53 percent of the ordinary share capital represented at the meeting, a payment of EUR ...

Further information
2019 CORPORATE
09.04.2019

Biotest AG: Biotest AG opens ninth plasma collection centre in Hungary

Biotest AG opens ninth plasma collection centre in Hungary- 21 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 9 April 2019. Biotest received an operating permit for its ninth plasma collection centre in Hungary from the country's national public health authority OTH. The centre is located in the capital Budapest and is one of Europe's most modern ...

Further information
2019 CORPORATE
28.03.2019

Biotest AG: Biotest increases operating result by EUR 20 million in 2018

Biotest increases operating result by EUR 20 million in 2018- EBIT rises to EUR 10.6 million- Sales grow by 5.9% to EUR 400.3 million- Biotest meets sales and EBIT forecast Dreieich, 28 March 2019. In financial year 2018, the Biotest Group generated sales of EUR 400.3 million from continuing operations, compared with EUR 378.1 million in the previous year. This corresponds to a 5.9% ...

Further information
2019 CORPORATE
12.03.2019

Biotest AG: Biotest receives approval for double concentrated Haemoctin(R) SDH for improved haemophilia A treatment in Europe

Biotest receives approval for double concentrated Haemoctin(R) SDH for improved haemophilia A treatment in Europe- Increased patient convenience: Volume reduction of the factor VIII concentrate Haemoctin(R) SDH with unchanged content of active ingredient - Biotest strengthens its position in the haemophilia market- Market launch in May 2019Dreieich, 12 March 2019. Biotest receives ...

Further information
2019 CORPORATE
07.03.2019

Biotest AG: Biotest increases operating result by EUR 20 million in 2018

Biotest increases operating result by EUR 20 million in 2018- EBIT rises to EUR 10.6 million- Sales grow by 5.9% to EUR 400.3 million- Biotest meets sales and EBIT forecast Dreieich, 07 March 2019. According to preliminary and unaudited figures, the Biotest Group increased sales in its continuing operations to EUR 400.3 million in the 2018 financial year. This corresponds to an ...

Further information
2019 CORPORATE
07.03.2019

Biotest AG: Dr Michael Ramroth to become new CEO of Biotest AG

Announcement according to Article 17 European Market Abuse Regulation (MAR)Dr Michael Ramroth to become new CEO of Biotest AGDreieich, 7 March 2019. The Supervisory Board of Biotest AG, in its meeting today, appointed Dr. Michael Ramroth (58) as Chairman of the Board of Management (CEO) effective May 1st, 2019. He will take over the role as CEO from Dr. Bernhard Ehmer (64) whose ...

Further information
2019 ADHOC
24.01.2019

Biotest AG: Biotest receives Intratect(R) approval for additional indications in 22 European countries

Biotest receives Intratect(R) approval for additional indications in 22 European countries- Additional fields of use in neurology (CIDP, MMN) and secondary immunodeficiencies (SID) - 40% of the globally produced immunoglobulins are used in the treatment of these diseases- Biotest plans to enter new marketsDreieich, 24 January 2019. Biotest has received the extension of the approved ...

Further information
2019 CORPORATE
12.12.2018

Biotest AG: Correction of a release from 11/12/2018 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Name: Biotest AG Street: Landsteinerstraße 5 Postal code: 63303 City: DreieichGermany Legal Entity Identifier (LEI): 529900JVX7RPXBLYUD892. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person ...

Further information
2018 PVR
11.12.2018

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Name: Biotest AG Street: Landsteinerstraße 5 Postal code: 63303 City: DreieichGermany Legal Entity Identifier (LEI): 529900JVX7RPXBLYUD892. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person ...

Further information
2018 PVR
04.12.2018

Biotest AG: Biotest AG takes next step in developing a new haemophilia therapeutic to target patient needs

Biotest AG takes next step in developing a new haemophilia therapeutic to target patient needs - Biotest exercises its option and receives exclusive rights for haemophilia on the use of Affibody's Albumod(TM) technology designed to prolong the half life of biopharmaceuticals - Preclinical results suggest a high probability of success for improving properties of innovative new ...

Further information
2018 CORPORATE
20.11.2018

Biotest AG: Hepatect(R) CP and Zutectra(R) show marked efficacy in the prevention of HBV reinfection after liver transplantation in long-term study

Hepatect(R) CP and Zutectra(R) show marked efficacy in the prevention of HBV reinfection after liver transplantation in long-term study- 371 liver transplanted patients observed over almost seven years - No hepatitis B virus reinfection was observed in patients receiving Zutectra(R)- Results support the long-term use of Hepatect(R) CP / Zutectra(R)- Biotest plans to enter further ...

Further information
2018 CORPORATE
15.11.2018

Biotest AG: Biotest AG acquires ninth plasma collection center in Germany

Biotest AG acquires ninth plasma collection center in Germany- 100% subsidiary Plasma Service Europe takes over plasma centre in Hanover- In the future, 20 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 15 November 2018. Plasma Service Europe GmbH, a 100% subsidiary of Biotest AG, has acquired a plasmapheresis centre in Hanover, Germany. The closing ...

Further information
2018 CORPORATE
14.11.2018

Biotest AG: Biotest increases sales in the first nine months of 2018 to

Biotest increases sales in the first nine months of 2018 to EUR 289.6 million- EBIT of EUR 5.1 million despite expenses of EUR 37.8 million for the Biotest Next Level project- Successful qualification of the process plant for the purification of IgG Next GenerationDreieich, 14 November 2018. In the first nine months of 2018, the Biotest Group reported revenue* of EUR 289.6 million. ...

Further information
2018 CORPORATE
12.11.2018

Biotest AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

Biotest AG hereby announces that the following financial reports shall be disclosed for the business year 2019: Report: Quarterly financial report within the 1st half-year (Q1) Date of disclosure / German: May 07, 2019 Date of disclosure / English: May 07, 2019 German: https://www.biotest.com/de/de/investor_relations/news_und_publikationen_/publikationen/quartalsberichte.cfm English: ...

Further information
2018 AFR
12.11.2018

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

Biotest AG hereby announces that the following financial reports shall be disclosed for the business year 2018: Report: Annual financial report Date of disclosure / German: March 28, 2019 Date of disclosure / English: March 28, 2019 German: https://www.biotest.com/de/de/investor_relations/news_und_publikationen_/publikationen/geschaeftsberichte.cfm English: ...

Further information
2018 AFR
21.08.2018

Biotest AG: Biotest AG announces successful completion of Mutual Recognition Procedure for marketing authorization of Cytotect(R) CP Biotest in twelve European countries

Biotest AG announces successful completion of Mutual Recognition Procedure for marketing authorization of Cytotect(R) CP Biotest in twelve European countries- Approval in four additional attractive European markets- Basis for future revenue growth with Cytotect(R) CP Biotest Dreieich, 21 August 2018. Biotest AG has announced today that the European Mutual Recognition Procedure ...

Further information
2018 CORPORATE
15.08.2018

Biotest AG: Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time

Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time- Transmission of CMV from pregnant women to the foetus is a main cause of post-natal complications in newborns- High medical need as 700 - 1,400 babies are born with developmental disorders due to CMV in Germany every year - ...

Further information
2018 CORPORATE
14.08.2018

Biotest AG: Biotest increases revenues to EUR 200.7 million in the first half of 2018

Biotest increases revenues to EUR 200.7 million in the first half of 2018- EBIT of EUR 0.6 million despite expenses of EUR 23.7 million for the Biotest Next Level project- Successful qualification of the process plant for the purification of IgG Next GenerationDreieich, 14 August 2018. In the first half of 2018, the Biotest Group reported revenue of EUR 200.7 million. This is an ...

Further information
2018 CORPORATE
01.08.2018

Biotest AG: Biotest has closed a transaction to sell all of its plasma collection centres in the United States to Grifols

Biotest has closed a transaction to sell all of its plasma collection centres in the United States to Grifols- Federal Trade Commission (FTC) approved sale of Biotest US Corporation and its operating subsidiary- Grifols paid USD 286 million for the acquisition of these assetsDreieich, 01 August 2018. Biotest AG announces today that the approval of the Federal Trade Commission (FTC), ...

Further information
2018 CORPORATE
19.07.2018

Biotest AG: Phase IIa study demonstrates favorable safety and tolerability profile for Biotest's monoclonal antibody BT-063 for treatment of systemic lupus erythematosus (SLE)

Phase IIa study demonstrates favorable safety and tolerability profile for Biotest's monoclonal antibody BT-063 for treatment of systemic lupus erythematosus (SLE)- Study meets primary endpoint for safety and tolerability- First signs of efficacy shown by early and sustained treatment effects- Potential of BT-063 for the treatment of Systemic Lupus Erythematosus (SLE) supported by ...

Further information
2018 CORPORATE
20.06.2018

Biotest AG: Biotest AG opens third plasma collection centre in Czech Republi

Biotest AG opens third plasma collection centre in Czech Republic- 19 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 20 June 2018. Biotest received an operating permit for its third plasma collection centre in Czech Republic from the country's national public health authority SUKL. The centre is located in Brno the south-eastern part of the country. ...

Further information
2018 CORPORATE
20.06.2018

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered ...

Further information
2018 PVR
29.05.2018

Biotest AG: Large data analysis for DSA after lung transplantation confirms impressive therapy outcome with Pentaglobin(R)

Large data analysis for DSA after lung transplantation confirms impressive therapy outcome with Pentaglobin(R)- The development of donor specific antibodies (DSA) can lead to graft rejection and thus to a greatly increased mortality risk- To date no convincing therapy concept for treatment of DSA after lung transplantation available- Relative reduction in mortality by more than 70% ...

Further information
2018 CORPORATE
23.05.2018

Biotest AG: Efficacy and safety of Cytotect(R) CP was demonstrated in patients after stem cell transplantation

Efficacy and safety of Cytotect(R) CP was demonstrated in patients after stem cell transplantation- 78% of "difficult-to-treat" patients responded to Cytotect(R) CP administration- 70% of patients cleared CMV infection to undetectable levels- Good tolerability confirmedDreieich, 23 May 2018. Cytomegalovirus (CMV) infection is a frequent complication leading to significant morbidity ...

Further information
2018 CORPORATE
15.05.2018

Biotest AG: Biotest AG: Annual general meeting approves payout of dividend

Biotest AG: Annual general meeting approves payout of dividend- Dividend payout of EUR 0.04 per preference shareDreieich/ Frankfurt a. M., 15 May 2018. At the annual general meeting (AGM) held on 15 May 2018 in Frankfurt/ Main, shareholders of Biotest AG approved the payment of a dividend. With 93,11 percent of the ordinary share capital represented at the meeting, a payment of EUR ...

Further information
2018 CORPORATE
15.05.2018

Biotest AG: Biotest increases revenues in the first quarter 2018 by 34%

Biotest increases revenues in the first quarter 2018 by 34%- Guidance confirmed- Q1 EBIT totalled to EUR -3.0 million after EUR-33.2 million in Q1 2017Dreieich, 15 May 2018. In the first quarter of 2018, the Biotest Group generated revenues in the amount of EUR 88.0 million, compared with EUR 65.7 million in the same period last year. This corresponds to an increase of 33.9%. The ...

Further information
2018 CORPORATE
03.05.2018

Biotest AG: New data from Biotest's monoclonal antibody-drug-conjugate (ADC) BT-062 in the therapy of solid tumors

New data from Biotest's monoclonal antibody-drug-conjugate (ADC) BT-062 in the therapy of solid tumors- Good tolerability and signs of efficacy in phase I/IIa clinical study- Very good effectiveness when combined with chemotherapeutic agent in preclinical studies on difficult to treat breast cancer- Biotest is seeking investors for further development of BT-062Dreieich, 3 May 2018. ...

Further information
2018 CORPORATE
22.03.2018

Biotest AG: Biotest reaches 2017 profit guidance

Biotest reaches 2017 profit guidance- Adjusted EBIT stable- Five new plasmapheresis centres opened in Europe- Biotest Next Level: building acceptance obtained and successful "Good Manufacturing Practice" (GMP) inspectionDreieich, 22 March 2018. Taking into account the results of the US business, which still belonged to the Biotest Group in 2017, the Biotest Group met the earnings ...

Further information
2018 CORPORATE
15.03.2018

Biotest AG: First patient with acquired fibrinogen deficiency treated in clinical phase III study of Biotest AG

Further information
2018 CORPORATE
13.03.2018

Biotest AG: Biotest supports a large international registry study to record data on use of Pentaglobin(R) in patients with severe bacterial infections

 Biotest supports a large international registry study to record data on use of Pentaglobin(R) in patients with severe bacterial infections- High medical need due to high mortality and large patient population- Aim of this registry is to record the use of Pentaglobin(R) under real life conditions- Results will provide data to optimize treatment strategies with Pentaglobin(R)- ...

Further information
2018 CORPORATE
27.02.2018

Biotest AG: Biotest reaches FY 2017 EBIT guidance

Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest reaches FY 2017 EBIT guidanceDreieich, 27 February 2018. According to preliminary and unaudited figures, the Biotest Group generated in the 2017 financial year revenue of EUR 378.1 million in the continuing operations, compared to EUR 408.0 million in the previous year. The main reason for the ...

Further information
2018 ADHOC
08.02.2018

Biotest AG: Tiancheng intends to enter into a domination and profit and loss transfer agreement with Biotest AG

Announcement according to Article 17 European Market Abuse Regulation (MAR)Tiancheng intends to enter into a domination and profit and loss transfer agreement with Biotest AGDreieich, 8 February 2018. Today, Tiancheng (Germany) Pharmaceutical Holdings AG, a holding company which is indirectly controlled by Creat Group Co., Ltd., informed the Company that it intends to enter into a ...

Further information
2018 ADHOC
02.02.2018

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered ...

Further information
2018 PVR
01.02.2018

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered ...

Further information
2018 PVR
31.01.2018

Biotest AG: Creat takeover of Biotest closed

 Creat takeover of Biotest closed- Transfer of tendered shares completed- Majority shareholding (approx. 90% of Biotest AG's ordinary shares and voting share capital) of Creat in Biotest Dreieich, 31 January 2018. On 19 January 2018 Biotest AG disclosed that the last remaining condition has been met for the takeover offer by Tiancheng (Germany) Pharmaceutical Holdings AG, ...

Further information
2018 CORPORATE
24.01.2018

Biotest AG: Biotest AG opens second plasma collection centre in Czech Republic

Biotest AG opens second plasma collection centre in Czech Republic- 19 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 24 January 2018. Biotest received an operating permit for its second plasma collection centre in Czech Republic from the country's national public health authority SUKL. The centre is located in Břeclav the south-eastern part of the ...

Further information
2018 CORPORATE
19.01.2018

Biotest AG: All conditions met for Creat takeover of Biotest

Announcement according to Article 17 European Market Abuse Regulation (MAR)All conditions met for Creat takeover of BiotestDreieich, 19. January 2018. Biotest AG disclosed today that foreign trade approval has been given by the U.S. Committee on Foreign Investment in the United States (CFIUS) and, thus, the last remaining condition has been met for the takeover offer by Tiancheng ...

Further information
2018 ADHOC
11.01.2018

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered office: J ...

Further information
2018 PVR
20.12.2017

Biotest AG: Trimodulin: concept for phase III study successfully coordinated with the authorities

Trimodulin: concept for phase III study successfully coordinated with the authorities- Clinical concept of the Phase III study is supported by the regulatory authorities- Optimized production process successful developedDreieich, 20 December 2017. In 2017, Biotest presented data from the Phase II study with Trimodulin (IgM Concentrate) in the indication severe community-acquired ...

Further information
2017 CORPORATE
06.12.2017

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 37v, 37w, 37y of the WpHG [the German Securities Act]

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 22, 2018 Date of disclosure / English: March 22, 2018 German: https://www.biotest.com/de/de/investor_relations/news_und_publikationen_/publikationen/geschaeftsberichte.cfm English: ...

Further information
2017 AFR
06.12.2017

Biotest AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Quarterly financial report within the 1st half-year (Q1) Date of disclosure / German: May 15, 2018 Date of disclosure / English: May 15, 2018 German: https://www.biotest.com/de/de/investor_relations/news_und_publikationen_/publikationen/quartalsberichte.cfm English: ...

Further information
2017 AFR
05.12.2017

Biotest AG: Biotest supports a randomized multicenter controlled trial in peritonitis (PEPPER trial) with Pentaglobin(R) lead by Aachen University

Biotest supports a randomized multicenter controlled trial in peritonitis (PEPPER trial) with Pentaglobin(R) lead by Aachen University- Trial investigates personalized treatment approaches with Biotest's Pentaglobin(R) in patients with abdominal inflammation (peritonitis)- Novel testing systems included to determine individual patient risksDreieich, 5 December 2017. Today, the ...

Further information
2017 CORPORATE
14.11.2017

Biotest AG: Biotest generates revenues of EUR 377.8 million in the first nine months 2017

Biotest generates revenues of EUR 377.8 million in the first nine months 2017- Successful regulatory inspection and approval of Biotest Next Level in August- Paul-Ehrlich Institute approves Phase III trial in the indication of acquired fibrinogen deficiencyDreieich, 14 November 2017. In the first nine months of the 2017 financial year, the Biotest Group generated revenue of EUR ...

Further information
2017 CORPORATE
07.11.2017

Tender Offer by Tiancheng (Germany) Pharmaceutical Holdings AG / Tiancheng withdrawal of application of transaction from CFIUS and refiling

Announcement according to Article 17 European Market Abuse Regulation (MAR)Tender Offer by Tiancheng (Germany) Pharmaceutical Holdings AG / Tiancheng withdrawal of application of transaction from CFIUS and refilingDreieich, 7 November 2017 - The Committee on Foreign Investment in the United States ("CFIUS") which currently reviews the tender offer by Tiancheng (Germany) ...

Further information
2017 ADHOC
06.11.2017

Biotest AG: Biotest AG opens eighth plasma collection centre in Hungary

Biotest AG opens eighth plasma collection centre in Hungary- 17 plasma collection centres in Europe and- 22 in the USA to ensure long-term plasma supplyDreieich, 6 November 2017. Biotest received an operating permit for its eighth plasma collection centre in Hungary from the country's national public health authority OTH. The centre is located in Kaposvár in the south-western part ...

Further information
2017 CORPORATE
26.10.2017

Correction of a release from 24.10.2017, 10:28 CET/CEST - Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights X Other reason:Exercise of financial instruments3. Details of person subject to the notification obligation Name: City and ...

Further information
2017 PVR
24.10.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments   Change of breakdown of voting rights X Other reason:Exercise of financial instruments3. Details of person subject to the notification obligation Name: City and country ...

Further information
2017 PVR
19.10.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered office: UBS ...

Further information
2017 PVR
18.10.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered office: J ...

Further information
2017 PVR
17.10.2017

Correction of a release from 16.10.2017, 12:50 CET/CEST - Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights X Other reason:Consequent increase of Trading Book holdings above 5%3. Details of person subject to the notification ...

Further information
2017 PVR
16.10.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights X Other reason:Consequent increase of Trading Book holdings above 5%3. Details of person subject to the notification ...

Further information
2017 PVR
13.10.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered office: J ...

Further information
2017 PVR
11.10.2017

Biotest AG: Biotest strengthens its position in the German haemophilia market with the introduction of new patient support services

Biotest strengthens its position in the German haemophilia market with the introduction of new patient support services- Biotest supports home treatment with a team of specialised nurses - New approach aims to tailor haemophilia therapy to individual patient needs - Biotest starts with the important haemophilia market Germany Dreieich, 11 October 2017. Medically controlled ...

Further information
2017 CORPORATE
30.08.2017

Biotest AG: Biotest AG: Annual general meeting approves payout of dividend

Biotest AG: Annual general meeting approves payout of dividend- Dividend payout of EUR 0.05 per ordinary share and EUR 0.07 per preference shareDreieich/ Frankfurt a. M., 30 August 2017. At the annual general meeting (AGM) held on 30 August 2017 in Frankfurt/ Main, shareholders of Biotest AG approved the payment of a dividend. With 79.6 percent of the ordinary share capital ...

Further information
2017 CORPORATE
23.08.2017

Biotest AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

Biotest AG hereby announces that the following financial reports shall be disclosed for the business year 2017: Report: Quarterly financial report within the 2nd half-year (Q3) Date of disclosure / German: November 14, 2017 Date of disclosure / English: November 14, 2017 German: http://www.biotest.com/de/de/investor_relations/news_und_publikationen_/publikationen/quartalsberichte.cfm English: ...

Further information
2017 AFR
14.08.2017

Biotest AG: Biotest reported sales of EUR 247.1 million in the first half of 2017

Biotest reported sales of EUR 247.1 million in the first half of 2017- Successful building inspection of the new building at Dreieich- Closing of the Public Takeover Offer is subject to the regulatory approval of the US foreign investment authority and of the Turkish antitrust authorityDreieich 14 August 2017. In the first half of 2017 the Biotest Group generated revenue of EUR ...

Further information
2017 CORPORATE
19.07.2017

Biotest AG: Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic

Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic- Long-term plasma supplier Cara Plasma was taken over by Biotest- Biotest has now 16 plasma collection centres in Europe and- 22 stations in the USA for the strategic safeguarding of plasma supplyDreieich, 19 July 2017. Today, Biotest took over its long-time plasma supplier Cara Plasma ...

Further information
2017 CORPORATE
22.06.2017

Biotest AG: Biotest reaches 2nd milestone in Biotest Next Level expansion project

Biotest reaches 2nd milestone in Biotest Next Level expansion project- Authorities grant building approval- Relocation activities of laboratories and offices for production start in June Dreieich, 22 June, 2017. Within the Biotest Next Level expansion project, Biotest will more than double its production capacity at the Dreieich site, invest over EUR 250 million and create ...

Further information
2017 CORPORATE
14.06.2017

Biotest AG: Biotest AG shareholders accept voluntary public tender offer by CREAT Group

Biotest AG shareholders accept voluntary public tender offer by CREAT GroupDreieich, 14 June, 2017. The shareholders of Biotest AG have accepted the voluntary public tender offer by Tiancheng (Germany) Pharmaceutical Holdings AG, the bidding company controlled by CREAT Group, by fulfilling the minimum acceptance condition of 75 percent of Biotest ordinary shares outstanding. This ...

Further information
2017 CORPORATE
12.06.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification   Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments   Change of breakdown of voting rights X Other reason:Rejection of offer of shareholders to purchase shares outside of takeover offer as shareholders will tender ...

Further information
2017 PVR
07.06.2017

Biotest AG: Biotest sold US therapy business to ADMA Biologics, Inc.

Biotest sold US therapy business to ADMA Biologics, Inc.- Biotest receives 50% minus one share of ADMA- Biotest receives also distribution rights of specified current product and a right of first offer for the distribution of future products of ADMA for Europe, Near and Middle East and selected Asian countries Dreieich, 7 June 2017. Biotest's US subsidiary, Biotest Pharmaceuticals ...

Further information
2017 CORPORATE
06.06.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification   Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered ...

Further information
2017 PVR
01.06.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification   Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered ...

Further information
2017 PVR
01.06.2017

Biotest AG: Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept tender offer of CREAT Group

Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept tender offer of CREAT Group Dreieich, 1 June, 2017. Today, the Management Board and Supervisory Board of Biotest AG published their joint reasoned statement, pursuant to Section 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz - WpÜG), ...

Further information
2017 CORPORATE
01.06.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification   Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered ...

Further information
2017 PVR
24.05.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification   Acquisition/disposal of shares with voting rights X Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered ...

Further information
2017 PVR
18.05.2017

Biotest AG: Publication of the offer document on the voluntary public tender for Biotest AG by CREAT Group

Publication of the offer document on the voluntary public tender for Biotest AG by CREAT Group- Offer document reaffirms the offer announced on April 7, 2017 - The Management Board and the Supervisory Board welcome and support the offer - The Management Board and the Supervisory Board will carefully review the offer document and issue a reasoned opinion pursuant to Section 27 WpÜG.- ...

Further information
2017 CORPORATE
17.05.2017

Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 37v, 37w, 37y of the WpHG [the German Securities Act]

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Financial report (half-year/Q2) Date of disclosure / German: August 14, 2017 Date of disclosure / English: August 14, 2017 German: http://www.biotest.com/de/de/investor_relations/news_und_publikationen_/publikationen/quartalsberichte.cfm English: ...

Further information
2017 AFR
16.05.2017

Biotest AG: Biotest AG opens seventh plasma collection centre in Hungary

Biotest AG opens seventh plasma collection centre in Hungary- 15 plasma collection centres in Europe and- 22 in the US to ensure long-term plasma supplyDreieich, 16 May 2017. Biotest received an operating permit for its seventh plasma collection centre in Hungary from the country's national public health authority OTH. The centre is located in the second largest Hungarian city of ...

Further information
2017 CORPORATE
10.05.2017

Biotest AG: Biotest reports revenue of EUR 110 million in the first quarter 2017

Biotest reports revenues of EUR 110.5 million in the first quarter 2017Dreieich, 10 May 2017. In the first quarter of 2017, the Biotest Group generated sales of EUR 110.5 million, after EUR 133.6 million in the same period of the previous year. This corresponds to a percentage decrease of 17.3 %. EUR 26.5 million of this decrease is attributable to sales reductions from the recall ...

Further information
2017 CORPORATE
04.05.2017

Correction of a release from 07.04.2017, 15:23 CET/CEST - Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Correction of a notification of Major Holding published on 07.04.20171. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification   Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights X Other reason:Conclusion of irrevocable undertaking agreement regarding the ...

Further information
2017 PVR
28.04.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered ...

Further information
2017 PVR
26.04.2017

Biotest AG: Biotest recalls human albumin and reduces forecast

Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest recalls human albumin and reduces forecastDreieich, 26 April 2017. In close co-operation with regulatory authorities, Biotest performed a batch recall of human albumin (Albiomin(R)) 5% und 20% Biotest injection solution. The batches in question had already been quarantined by Biotest on 13 April ...

Further information
2017 ADHOC
26.04.2017

Biotest AG: Voluntary recall of human albumin

Biotest: Voluntary recall of human albumin- Already quarantined batches of human albumin are recalled- Consequences of the one-time effect on Sales and EBIT are currently being evaluated - As a precaution, guidance is being reduced Dreieich, 26 April 2017 Today, Biotest has informed its customers about the recall of several batches of human albumin. The batches in question had ...

Further information
2017 CORPORATE
19.04.2017

Biotest AG: Biotest AG opens sixth plasma collection centre in Hungary

Biotest AG opens sixth plasma collection centre in Hungary- 14 plasma collection centres in Europe and- 22 in the US to ensure long-term plasma supplyDreieich, 19 April 2017. Biotest received an operating permit for its sixth plasma collection centre in Hungary from the country's national public health authority OTH. The centre is in the western Hungarian city of Székesfehérvár and ...

Further information
2017 CORPORATE
13.04.2017

Biotest AG: Biotest informs about limited availability of albumin

Biotest informs about limited availability of albumin- Due to an equipment failure the availability of albumin is currently limited- Consequences on sales and annual results are currently not assessable Dreieich, 13 April 2017 Today, Biotest has started to inform its customers about an expected albumin supply shortage within the coming months. This is due to an ...

Further information
2017 CORPORATE
13.04.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered ...

Further information
2017 PVR
11.04.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered ...

Further information
2017 PVR
11.04.2017

Correction of a release from 06.04.2017, 14:54 CET/CEST - Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

AnnouncementJO HAMBRO Capital Management Limited informed us that they retract their notification published by us on 6h April 2017, as no thresholds had been crossed which are relevant for ...

Further information
2017 PVR
07.04.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification   Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights X Other reason:Conclusion of irrevocable undertaking agreement regarding the tendering of shares in a takeover offer3. ...

Further information
2017 PVR
07.04.2017

Biotest AG: Takeover Offer: Chinese strategic investor Creat to make a voluntary public takeover offer for the shares of Biotest AG

Announcement according to Article 17 European Market Abuse Regulation (MAR)Takeover Offer: Chinese strategic investor Creat to make a voluntary public takeover offer for the shares of Biotest AGDreieich, 7 April 2017. Biotest AG, Tiancheng International Investment Limited, Hong Kong, and Blitz 17-623 AG (in future: Tiancheng (Germany) Pharmaceutical Holdings AG), affiliated ...

Further information
2017 ADHOC
07.04.2017

Biotest AG: Biotest AG and Creat enter into Business Combination Agreement

Biotest AG and Creat enter into Business Combination Agreement - Chinese strategic investor Creat to make a voluntary public takeover offer- Shareholders will be offered EUR 28.50 in cash per Biotest ordinary share and EUR 19.00 in cash per Biotest preference share- Offer represents a premium of 55% per ordinary share and 15% per preference share to the three month volume weighted ...

Further information
2017 CORPORATE
06.04.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered ...

Further information
2017 PVR
29.03.2017

Biotest AG: Discussions regarding business combination

Announcement according to Article 17 European Market Abuse Regulation (MAR)Discussions regarding business combinationDreieich, 29 March 2017. Biotest Aktiengesellschaft and Creat Group Corporation, a leading Chinese investment group, are currently in discussions regarding a potential business combination. Creat is a long-term strategic investor.Creat Group Corporation indicated ...

Further information
2017 ADHOC
29.03.2017

Biotest AG: Discussions regarding possible business combination

Discussions regarding possible business combinationDreieich, 29 March 2017. Biotest AG announced today that it is in discussion with Creat Group Corporation (Creat), a leading Chinese investment group, regarding a potential business combination. Creat is a long-term strategic investor.Creat has indicated certain key parameters of a potential combination to be implemented through a ...

Further information
2017 CORPORATE
24.03.2017

Biotest AG: ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062)

ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062) - License agreement with ImmunoGen will continueDreieich, 24 March 2017. Since 2006 a collaboration and licensing agreement between Biotest and ImmunoGen, Inc., MA (USA) (ImmunoGen) is in place for the use of ImmunoGen's antibody-drug conjugate ...

Further information
2017 CORPORATE
01.03.2017

Biotest AG: Recombinant clotting factor VIII with the name Vihuma(R) approved

Recombinant clotting factor VIII with the name Vihuma(R) approved - Market launch in Germany end of April 2017 - Vihuma(R) is a 4th generation recombinant human factor VIII preparation from a human cell line - Vihuma(R) is an optimal portfolio supplement for BiotestDreieich, 1 March 2017. Today, the European Commission (EC) has approved the first, 4th generation human factor VIII ...

Further information
2017 CORPORATE
17.02.2017

Biotest AG: Proceedings against Biotest AG have been closed

Proceedings against Biotest AG have been closedDreieich, 17 February 2017. Biotest AG has agreed with the Frankfurt public prosecution on a mutual termination of the proceedings against the company due to the Russia business.Besides the tax payment already communicated on 4 November 2016, Biotest has paid a corporate fine in the amount of EUR1.0 million. Thereby proceedings against ...

Further information
2017 CORPORATE
16.02.2017

Biotest AG: EUR 64.4 million operating profit in core business of Biotest

EUR 64.4 million operating profit in core business of Biotest Dreieich, 16 February 2017. In line with the strategic realignment Biotest has restructured its US Therapy business. In the next years Biotest will focus in the US primarily on the plasma collection business and extend this business. Through the cooperation with ADMA Biologics Inc. Biotest will have access to new special ...

Further information
2017 CORPORATE
27.01.2017

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights   Other reason:3. Details of person subject to the notification obligation Name: City and country of registered ...

Further information
2017 PVR
25.01.2017

Biotest AG: First patient treated in the next clinical phase III study of IgG Next Generation in the indication Primary Immune Thrombocytopenia (ITP)

First patient treated in the next clinical phase III study of IgG Next Generation in the indication Primary Immune Thrombocytopenia (ITP)- Study no. 992 is the second pivotal phase III study in the clinical program for IgG Next Generation, a novel development of our polyvalent immunoglobulin G- Study design was agreed with European regulatory authorities and results will serve as ...

Further information
2017 CORPORATE
23.01.2017

Biotest AG: Biotest to sell US therapy business to ADMA Biologics, Inc., and will receive approximately 50% of the shares of ADMA Biologics, Inc. at closing, which is anticipated to occur in the first half of 2017.

Biotest to sell US therapy business to ADMA Biologics, Inc., and will receive approximately 50% of the shares of ADMA Biologics, Inc. at closing, which is anticipated to occur in the first half of 2017. - Earnings before interest and taxes of Continued Operations in 2016 increases by approx. EUR30 million- Biotest secures participation in future success of ADMA Biologics, Inc. - ...

Further information
2017 CORPORATE
23.01.2017

Biotest AG: Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc Dreieich, 23 January 2017. Biotest's US subsidiary, Biotest Pharmaceuticals Corporation, Boca Raton, Florida, USA, (BPC), has entered into a definitive agreement with ADMA ...

Further information
2017 ADHOC
06.12.2016

Biotest AG: Encouraging data of Indatuximab Ravtansine (BT-062) in combination therapy in advanced Multiple Myeloma

Encouraging data of Indatuximab Ravtansine (BT-062) in combination therapy in advanced Multiple Myeloma- New data from BT-062 in combination therapy presented at 58th annual conference of the American Society of Hematology- Clinical benefit seen in large majority of patients with advanced multiple myeloma- Very good response achieved in patients who did not respond adequately to ...

Further information
2016 CORPORATE
01.12.2016

Biotest AG: Biotest opens new plasma collection centre in Kearney, Nebraska, USA

Biotest opens new plasma collection centre in Kearney, Nebraska, USA - 13 plasma collection centres in Europe - 22 in the US to ensure long-term plasma supplyDreieich, 1 December 2016. Biotest Pharmaceuticals Corporation, Boca Raton, USA (BPC), a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of plasma proteins and biological products, is pleased to announce the ...

Further information
2016 CORPORATE
23.11.2016

Biotest AG: Biotest supports a large international retrospective study to record data on clinical use of Cytotect(R) after heart and lung transplantation

Biotest supports a large international retrospective study to record data on clinical use of Cytotect(R) after heart and lung transplantation- Results will provide a basis for design of a new transplantation study- Evaluation of the optimal treatment regimen as a basis for adapting international treatment guidelines- Marked medium-term increase of the market potential of ...

Further information
2016 CORPORATE
10.11.2016

Biotest AG: Biotest increases revenues by 9%

Biotest increases revenues by 9%- EBIT increased to EUR 26.1 million- Cash flow of EUR 46.9 million- Guidance confirmedDreieich, 10 November 2016. In the first nine months of 2016, the Biotest Group generated revenues of EUR 455.6 million, after EUR 417.9 million in the same period of the previous year. This corresponds to an increase of 9.0%. The largest sales increase was ...

Further information
2016 CORPORATE
08.11.2016

Biotest AG: First patient treated in global clinical phase III study of IgG Next Generation in the indication Primary Immunodeficiency Disease (PID)

First patient treated in global clinical phase III study of IgG Next Generation in the indication Primary Immunodeficiency Disease (PID) - Study no. 991 marks the first phase III study in the worldwide clinical development program for IgG Next Generation, a novel development of our polyvalent immunoglobulin G - Study design was agreed with US and European regulatory authorities and ...

Further information
2016 CORPORATE
04.11.2016

Biotest AG: Altered tax assessments for 2005-2008 lead to a decrease of claims against Biotest AG - proceedings against Biotest AG are close to be completed

Announcement according to Article 17 European Market Abuse Regulation (MAR) Altered tax assessments for 2005-2008 lead to a decrease of claims against Biotest AG - proceedings against Biotest AG are close to be completed Dreieich, 4 November 2016. Today the Finanzamt Offenbach am Main (tax office Offenbach am Main) served to Biotest AG altered tax assessments for corporate ...

Further information
2016 ADHOC
03.11.2016

Biotest AG: Biotest AG will offer recombinant factor VIII from 2017

Biotest AG will offer recombinant factor VIII from 2017- Cooperation with Octapharma for German-speaking markets - Fourth-generation recombinant human factor VIII preparation from a human cell line Dreieich, 3 November 2016. Biotest AG will be adding a recombinant factor VIII preparation to its haemophilia portfolio which will be produced by using a human cell line from early 2017 ...

Further information
2016 CORPORATE
01.11.2016

Biotest AG: Interim analysis supports continuation of clinical phase IIa trial in Systemic Lupus Erythematosus (Study No. 990)

Interim analysis supports continuation of clinical phase IIa trial in Systemic Lupus Erythematosus (Study No. 990)- Independent Data Safety Monitoring Board (DSMB) recommends to start part 2 of clinical study No. 990- DSMB did not identify any safety concerns- SLE is an indication with remaining high medical needDreieich, 1 November 2016. Biotest AG announced today that the Data ...

Further information
2016 CORPORATE
28.09.2016

Biotest AG: Biotest opens new plasma collection centre in Vermillion, South Dakota, USA

Biotest opens new plasma collection centre in Vermillion, South Dakota, USA- 13 plasma collection centres in Europe- 21 in the US to ensure long-term plasma supplyDreieich, 28 September 2016. Biotest Pharmaceuticals Corporation (BPC), Boca Raton, USA, a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of plasma proteins and biological products, is pleased to announce ...

Further information
2016 CORPORATE
11.08.2016

Biotest AG: Biotest increases EBIT significantly

Biotest increases EBIT significantly- Strong EBIT increase to EUR 18.2 million vs. EUR 2.3 million- Increase of revenue by 6.4% to EUR 306 million - Operating Cash flow increased to EUR 50 millionDreieich, 11 August 2016. In the first half of 2016 the Biotest Group recorded revenue of EUR 306.1 million, representing an increase of 6.4% compared to the same period of the previous ...

Further information
2016 CORPORATE
03.08.2016

Biotest AG: Altered Tax Assessments for 2005 - 2008

Announcement according to Article 17 European Market Abuse Regulation (MAR) Altered Tax Assessments for 2005 - 2008 Dreieich, 3 August 2016. Today the Finanzamt Offenbach am Main (tax office Offenbach am Main) served to Biotest AG altered tax assessments for corporate tax, solidarity tax and trade tax for the years 2005 until 2008. The alterations are based on the ...

Further information
2016 ADHOC
29.07.2016

Biotest AG: Biotest AG opens fifth plasma collection centre in Hungary

Biotest AG opens fifth plasma collection centre in Hungary- Thirteen plasma collection centres in Europe and- Twenty in the US to ensure long-term plasma supplyDreieich, 29 July 2016. Biotest received an operating permit for its fifth plasma collection centre in Hungary from the country's national public health authority OTH. The centre is in the southern Hungarian city of Szeged ...

Further information
2016 CORPORATE
27.07.2016

Biotest AG: Biotest opens new plasma collection centre in Clemson, South Carolina, USA

Biotest opens new plasma collection centre in Clemson, South Carolina, USA - 12 plasma collection centres in Europe - 20 in the US to ensure long-term plasma supplyDreieich, 27 July 2016. Biotest Pharmaceuticals Corporation, Boca Raton, USA (BPC), a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of plasma proteins and biological products, is pleased to announce the ...

Further information
2016 CORPORATE
21.07.2016

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification   Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights X Other reason:Notification of Voting Rights pursuant to section 41 § 4g WpHG3. Details of person subject to the ...

Further information
2016 PVR
14.07.2016

Biotest AG: Former Biotest employee sentenced

Former Biotest employee sentencedDreieich, 14 July 2016. Today, the Landgericht Darmstadt (District Court Darmstadt, Germany) sentenced a former Biotest representative for Russia to imprisonment of 5 years and 9 months. According to the judgement of the court, the former employee is guilty of complicity in fraud and tax evasion in the years 2007-2011. Her husband was sentenced to ...

Further information
2016 CORPORATE
24.05.2016

Biotest AG: Biotest opens new plasma collection centre in Brookings, South Dakota, USA

Biotest opens new plasma collection centre in Brookings, South Dakota, USA- 12 plasma collection centres in Europe- 19 in the US to ensure long-term plasma supplyDreieich, 24 May 2016. Biotest Pharmaceuticals Corporation, Boca Raton, USA (BPC), a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of plasma proteins and biological products, is pleased to announce the ...

Further information
2016 CORPORATE
23.05.2016

Biotest AG: Pentaglobin(R) showed a significant survival benefit in severe infections caused by multidrug resistant bacteria

Pentaglobin(R) showed a significant survival benefit in severe infections caused by multidrug resistant bacteria- Additional therapy with Pentaglobin(R) significantly reduced the relative mortality risk by 33% in patients with confirmed resistance to antibiotics- Greatest relative survival benefit of 39% was seen in subgroup with infections by extensively drug resistant (XDR) ...

Further information
2016 CORPORATE
12.05.2016

Biotest AG: Biotest increases EBIT significantly in the first quarter 2016

Biotest increases EBIT significantly in the first quarter 2016- Increased Guidance confirmed- Good start of cooperation with Kedrion- Dividend proposedDreieich, 12 May 2016. In the first quarter of 2016, the Biotest Group generated revenue of EUR 147.1 million, after EUR 142.5 million in the same period of the previous year. This corresponds to a percentage increase of 3.2 %. All ...

Further information
2016 CORPORATE
12.05.2016

Biotest AG: Annual general meeting approves payout of dividend

Biotest AG: Annual general meeting approves payout of dividend- Dividend payout of EUR 0.02 per ordinary share and EUR 0.04 per preference shareDreieich/ Frankfurt a. M., 12 May 2016. At the annual general meeting (AGM) held on 12 May 2016 in Frankfurt/ Main, shareholders of Biotest AG approved the payment of a dividend. With 74,4 percent of the ordinary share capital represented at ...

Further information
2016 CORPORATE
07.04.2016

Biotest AG: Biotest AG opens fourth plasma collection centre in Hungary

Biotest AG opens fourth plasma collection centre in Hungary- Twelve plasma collection centres in Europe and- Eighteen in the US to ensure long-term plasma supplyDreieich, 7 April 2016. Yesterday, Biotest received an operating permit for its fourth plasma collection centre in Hungary from the country's pharmaceutical regulatory authority, OGYÉI. The centre is in the western ...

Further information
2016 CORPORATE
23.03.2016

Biotest AG: Increase of guidance 2016 by more than 10%

Increase of guidance 2016 by more than 10%- Positive operating cash flow of EUR 38.1 million in 2015- Equity ratio of 42.8%Dreieich, 23 March 2016. 2016. In the 2015 financial year, the Biotest Group generated revenues in the amount of EUR 589.6 million after EUR 582.0 million in the previous year. This corresponds to a 1.3 % increase.In the financial year 2015, the EBIT amounts to ...

Further information
2016 CORPORATE
16.03.2016

Biotest AG: IgM Concentrate: Remarkable relative reduction in mortality of more than 50% in subgroup of patients

IgM Concentrate: Remarkable relative reduction in mortality of more than 50% in subgroup of patients- Favourable new data of phase II trial with IgM Concentrate in patients with severe Community Acquired Pneumonia (sCAP) published at ISICEM Symposium- Strong data justifies phase III developmentDreieich, March 16, 2016. Biotest announces further results of a phase II trial with IgM ...

Further information
2016 CORPORATE
11.02.2016

Biotest AG: Biotest exceeds EBIT guidance for 4th quarter 2015

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest exceeds EBIT guidance for 4th quarter 2015 Dreieich, 11. February 2016. According to preliminary and unaudited figures, the Biotest Group exceeds its EBIT guidance published in November 2015 in the amount of EUR 5-10 million for the fourth quarter 2015 and reports an EBIT of EUR 10.2 million in the ...

Further information
2016 ADHOC
11.02.2016

Biotest AG: Correction of the Ad hoc announcement dated February 11th 2016: Accidentally an incorrect preliminary and unaudited EBIT for the fiscal year 2015 was published. The EBIT amounts to EUR -71.8 million and not to EUR -72.3 million. Below, the corrected announcement:

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Correction of the Ad hoc announcement dated February 11th 2016: Accidentally an incorrect preliminary and unaudited EBIT for the fiscal year 2015 was published. The EBIT amounts to EUR -71.8 million and not to EUR -72.3 million. Below, the corrected announcement: Biotest exceeds EBIT guidance for 4th quarter ...

Further information
2016 ADHOC
19.01.2016

Biotest enters into an exclusive cooperation agreement with Kedrion Biopharma for the distribution of Bivigam® in the U.S.

Further information
2016 CORPORATE
14.01.2016

Biotest AG: Kreissparkasse Biberach continues to be major shareholder of Biotest

PRESS RELEASEKreissparkasse Biberach continues to be major shareholder of BiotestDreieich, 14. January 2016. "Biotest has today published a notification of existing voting rights, pursuant to section 41, para. 4f of the German Securities Trading Act (WpHG) of the District of Biberach which submitted this notification controlling the Kreissparkasse Biberach ("KSK"). Even if this notification of ...

Further information
2016 CORPORATE
14.01.2016

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification   Acquisition/disposal of shares with voting rights   Acquisition/disposal of instruments   Change of breakdown of voting rights X Other reason: Notification of Voting Rights pursuant to section 41 §7f WpHG3. Details of person subject to the ...

Further information
2016 PVR
14.01.2016

Biotest AG: Pentaglobin(R) showed encouraging results in the treatment of donor specific antibodies after lung transplantation

Pentaglobin(R) showed encouraging results in the treatment of donor specific antibodies after lung transplantation- In lung transplantation early new donor specific antibodies (DSA) are risk factors for mortality and graft rejection- Pentaglobin showed very good efficacy in patients who showed early DSA development after lung transplantation- Patients with early new DSA but treated ...

Further information
2016 CORPORATE
12.01.2016

Biotest AG: Biotest receives approval in the European Union for the early use of Zutectra(R) after liver transplantation

Biotest receives approval in the European Union for the early use of Zutectra(R) after liver transplantation- Application of the subcutaneous hepatitis B hyperimmunoglobulin Zutectra(R) already one week after liver transplantation approved- Market position as a leading provider of hepatitis B hyperimmunoglobulins strengthenedDreieich, 12 January 2016. The European Commission has ...

Further information
2016 CORPORATE
10.12.2015

Biotest AG: Successful start of the operation of the new plasma receiving area and the virological laboratories

Successful start of the operation of the new plasma receiving area and the virological laboratories- Authorities issue operating license for the building- Storage capacity for human plasma expanded to 1,440 pallet slots- Another milestone reached in the context of the Biotest Next Level capacity expansion programmeDreieich, 10 December 2015. After just two years of construction, ...

Further information
2015 CORPORATE
01.12.2015

Biotest AG: Biotest proceeds into phase III programme in congenital fibrinogen deficiency

Biotest proceeds into phase III programme in congenital fibrinogen deficiency- Fibrinogen concentrate shows good efficacy and safety profile based on preliminary data- Preliminary data on pharmacokinetic profile are comparable to licensed products- German authority (Paul-Ehrlich-Institut) approved the extension of ongoing study to phase a I/III trialDreieich, 1 December 2015. ...

Further information
2015 CORPORATE
23.11.2015

Biotest AG: Biotest receives positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for the early use of Zutectra(R) after liver transplantation

Biotest receives positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for the early use of Zutectra(R) after liver transplantation- Market position as a leading provider of hepatitis B hyperimmunoglobulins strengthened- Biotest expects European approval in February 2016Dreieich, 23 November 2015. The Committee for Medicinal Products for Human Use ...

Further information
2015 CORPORATE
10.11.2015

Biotest AG: Biotest establishes basis for significantly higher earnings potentia

Biotest establishes basis for significantly higher earnings potential- Profitable core business despite setback in Q3 2015- Focus on core business increases planning reliability- Good progress of plasma protein development projectsDreieich, 10 November 2015. At today's analyst conference in Frankfurt am Main, the Board of Management will discuss how the continued profitable growth ...

Further information
2015 CORPORATE
09.11.2015

Biotest AG: Biotest to present data from TREAT 2b trial at The American College of Rheumatology (ACR) 2015 Annual Meeting

Biotest to present data from TREAT 2b trial at The American College of Rheumatology (ACR) 2015 Annual Meeting - Presentation of clinical results from TREAT 2b trial (T cell REgulating Arthritis Trial 2b), evaluating the efficacy, safety and tolerability of its investigational monoclonal antibody, Tregalizumab (BT-061), plus methotrexate combination therapy in patients with moderate ...

Further information
2015 CORPORATE
06.11.2015

Biotest AG: Letter to Shareholders

LETTER TO SHAREHOLDERSNovember 4, 2015Dear Shareholders,The past weeks have been challenging for all of us. As you know, we announced impairments totalling EUR 84 million on 20 October 2015, resulting in negative EBIT of EUR -82 million for the first three quarters. Most of the impairments and write-downs relate to our US therapy activities. The US plasma collection business was not affected. In ...

Further information
2015 CORPORATE
20.10.2015

Biotest AG: Impairment of US business and investments in Europe

PRESS RELEASEBiotest: Impairment of US business and investments in EuropeDreieich, 20 October 2015. Biotest AG announces impairments today totalling to EUR 84 million, leading to a negative third-quarter result (Q1-Q3 2015 EBIT: EUR -82 million). The impairment primarily relates to the company's US therapy activities. The US plasma collection business remains unaffected. The expansion of the ...

Further information
2015 CORPORATE
20.10.2015

Biotest AG: Impairment of US business and change of guidance

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest: Impairment of US business and change of guidance Dreieich, 20 October 2015: Biotest AG announces to make impairments today totalling EUR84 million, leading to a negative third-quarter result (EBIT Q1-Q3 2015: -EUR82 million). The impairment primarily relates to the company's US Therapy activities, ...

Further information
2015 ADHOC
13.10.2015

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

On October 13, 2015, ETHENEA Independant Investors S.A., Munsbach, Luxembourg has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, have exceeded the 3% threshold of the Voting Rights on July 15, 2015 and on that day amounted to 3.03% (this corresponds to 600000 Voting Rights). 13.10.2015 The DGAP Distribution ...

Further information
2015 PVR
06.10.2015

Biotest AG: Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus (SLE)

Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus (SLE)- First patient included and treated in the multicentric, placebo-controlled phase IIa trial - SLE is an indication with high medical need Dreieich, October 6, 2015. The phase IIa clinical study ...

Further information
2015 CORPORATE
30.09.2015

Biotest AG: Biotest AG continues cooperation with ADMA Biologics, Inc. for the RSV hyperimmunoglobulin RI-002

Biotest AG continues cooperation with ADMA Biologics, Inc. for the RSV hyperimmunoglobulin RI-002- Biologic Licence Application submitted to Food and Drug Administration after successful phase III trialDreieich, September 30, 2015. In accordance with the license agreement entered on December 31, 2012 Biotest AG (Biotest) made a milestone payment following ADMA Biologics, Inc., New ...

Further information
2015 CORPORATE
14.08.2015

Correction of a release from 14.08.2015, 11:11 CET - Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

On August 13, 2015, BayernInvest Kapitalverwaltungsgesellschaft mbH, 80333 Munich, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, have fallen below the 3% threshold of the Voting Rights on August 11, 2015 and on that day amounted to 2.46% (this corresponds to 487368 Voting Rights). 1.92% of Voting ...

Further information
2015 PVR
14.08.2015

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

On August 13, 2015, Bayerininvest Kapitalverwaltungsgesellschaft mbH, 80333 Munich, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, have fallen below the 3% threshold of the Voting Rights on August 11, 2015 and on that day amounted to 2.46% (this corresponds to 487368 Voting Rights). 1.92% of Voting ...

Further information
2015 PVR
11.08.2015

Biotest AG: Biotest increases revenues in first half year 2015 by 8.9%

Biotest increases revenues in first half year 2015 by 8.9%- Clinical development of BT-061 will be discontinued- Capacity expansion at headquarter Dreieich on schedule- Board of management confirms EBIT guidance of EUR 20-25 millionDreieich, 11. August 2015. The Biotest Group recorded significant year-on-year sales growth in the first half of 2015. The Group recorded revenue of EUR ...

Further information
2015 CORPORATE
14.07.2015

Biotest AG: Biotest stock split becomes effective as scheduled - first trading day on July 15

Biotest stock split becomes effective as scheduled - first trading day on July 15- Stock listing and shareholders' deposits will be changed on July 15th in a ratio 1:3- Shares in security accounts will be converted automatically- Unexecuted orders will expire after July 14Dreieich, 14 July 2015. The stock split with capital increase from company funds was recorded in the commercial ...

Further information
2015 CORPORATE
08.07.2015

Biotest AG: Biotest AG reorganises stock exchange listing due to share split on 15 July 2015

Biotest AG reorganises stock exchange listing due to share split on 15 July 2015- Share split at a ration of 1:3- By share split and capital increase from company's funds the shareholder structure will not changeDreieich, 8 July 2015. Biotest AG reorganises the stock exchange listing of its shares at a ratio of 1:3 due to the share split on 15 July 2015. Therefore the price per ...

Further information
2015 CORPORATE
01.07.2015

Biotest AG: Biotest and CEVEC Pharmaceuticals enter into a License Agreement regarding a cell line system for the production of tailor-made proteins

Biotest and CEVEC Pharmaceuticals enter into a License Agreement regarding a cell line system for the production of tailor-made proteins- The agreement relates to CEVEC's proprietary cell line (expression system) for the development, production and commercialization of proteins to treat the symptoms of Haemophilia patientsDreieich, July 1, 2015. Biotest AG and CEVEC Pharmaceuticals ...

Further information
2015 CORPORATE
30.06.2015

Biotest AG: Biotest's IgM Concentrate shows encouraging results in life-threatening pneumonia

Biotest's IgM Concentrate shows encouraging results in life-threatening pneumonia - Phase II trial with IgM Concentrate completed in patients with severe community acquired pneumonia (sCAP) requiring mechanical ventilation- Encouraging trend in reducing duration of ventilation as well as mortalityDreieich, June 30, 2015. Biotest announces results of the phase II trial with IgM ...

Further information
2015 CORPORATE
30.06.2015

Biotest AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that at the end of the month June 2015 the number of Voting Rights amounts to a total of 19785726 Voting Rights. It is planned that the technical execution will take place on July 15th, 2015. 30.06.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and ...

Further information
2015 NVR
24.06.2015

Biotest AG: Biotest regains rights to Tregalizumab (BT-061)

Biotest regains rights to Tregalizumab (BT-061) - AbbVie exercised its rights to opt-out of the worldwide license, development and commercialisation agreementDreieich, June 24, 2015. Biotest AG today announced that AbbVie and Biotest will end their collaboration on the development and commercialisation of Tregalizumab (BT-061). AbbVie has exercised its rights to opt-out of the ...

Further information
2015 CORPORATE
01.06.2015

Biotest AG: Biotest AG and Affibody AB enter into a Research License and Option Agreement regarding the Albumod(TM) technology platform

Biotest AG and Affibody AB enter into a Research License and Option Agreement regarding the Albumod(TM) technology platform- Affibody's Albumod(TM) technology is designed to prolong the duration of action of biopharmaceuticals and therefore potentially enhances the efficacy of biopharmaceuticalsDreieich, Germany and Solna, Sweden, 1 June 2015. Biotest AG and Affibody AB today ...

Further information
2015 CORPORATE
07.05.2015

Biotest AG: Annual general meeting approves increase of dividend and a share split

PRESS RELEASEBiotest AG: Annual general meeting approves increase of dividend and a share split - Dividend payment of EUR 0.60 per ordinary share and EUR 0.66 per preference share - Share split with the relation of one to three approvedDreieich/ Frankfurt a. M., 7 May 2015. At the annual general meeting (AGM) held on 7 May 2015 in Frankfurt am Main, shareholders of Biotest AG approved the ...

Further information
2015 CORPORATE
07.05.2015

Biotest AG: Biotest increases revenues by 16,6%

Biotest increases revenues by 16,6%- Higher Sales in the US- Capacity expansion at headquarter Dreieich in scheduleDreieich, 7 May 2015. The Biotest Group again succeeded to increase revenues in the first three months of 2015. The Group generated revenue of EUR 142.5 million in the period from January to March 2015. This represents an increase of 16.6 % compared to the same period ...

Further information
2015 CORPORATE
24.04.2015

Biotest AG: Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million

Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million- No safety concerns were noted for the BT-061 study - AbbVie, will decide within 90 days whether to continue the co-development on tregalizumab (BT-061)Dreieich, April 24, 2015 - Biotest today announced ...

Further information
2015 CORPORATE
24.04.2015

Biotest AG: Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of - EUR 30 million

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of - EUR 30 million Dreieich, April 24, 2015 - Biotest today announced top line results from the TREAT 2b study [T cell REgulating Arthritis Trial 2b], ...

Further information
2015 ADHOC
23.04.2015

Biotest AG: Biotest proves effective protection from Hepatitis B virus reinfection after liver transplantation in 'ZEUS' study with subcutaneous hepatitis B immunoglobulin Zutectra (R)

Biotest proves effective protection from Hepatitis B virus reinfection after liver transplantation in "ZEUS" study with subcutaneous hepatitis B immunoglobulin Zutectra- The Zutectra-Early-Use-Study (ZEUS) demonstrates safe and effective switch from high dose intravenous hepatitis B immunoglobulin (HBIG) to subcutaneous HBIG, Zutectra(R), at the earliest one week after liver ...

Further information
2015 CORPORATE
23.04.2015

Biotest AG: Biotest presents new clinical and preclinical results of Civacir(R) at The 50th International Liver Congress 2015 in Vienna

Biotest presents new clinical and preclinical results of Civacir(R) at The 50th International Liver Congress 2015 in Vienna- Preliminary clinical results suggest that Civacir(R) reduces the hepatitis C virus recurrence rate after liver transplantation in an impressive way to 5% (1 out of 21 patients)- Preclinical data shows activity of Civacir(R) against different hepatitis C virus ...

Further information
2015 CORPORATE
13.04.2015

Biotest AG: Biotest announces the opening of a plasma collection facility in Conway, Arkansas, US and the relocation of it's plasma collection Facility in San Antonio, Texas, US

Biotest announces the opening of a plasma collection facility in Conway, Arkansas, US and the relocation of it's plasma collection Facility in San Antonio, Texas, US- Total number of plasma collection centers in the US now eighteen.Dreieich, 13 April, 2015. Biotest is pleased to announce the addition of its newest plasma collection in Conway, Arkansas, US. The over 16,000 square ...

Further information
2015 CORPORATE
24.03.2015

Biotest AG: Biotest increases sales by 16.2%

Biotest increases sales by 16.2%- Earnings before interest and tax (EBIT) at EUR 53.4 million- Expansion project "Biotest Next level" in timeline and budget- Share split with the relation of 1:3 to be proposed at AGM on May 7th, 2015Dreieich, 24 March 2015. The Biotest Group generated sales of EUR 582.0 million in the 2014 financial year. This amounts to a significant increase of ...

Further information
2015 CORPORATE
17.03.2015

Biotest AG: Biotest AG: Biotest proposes capital increase from capital funds and share split to General Meeting

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG: Biotest proposes capital increase from capital funds and share split to General Meeting - Proposed capital increase without issuing new shares - Proposed share split with the relation of one to three Dreieich, 17 March 2015. Biotest AG will propose a capital increase from capital funds and ...

Further information
2015 ADHOC
10.03.2015

Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 24, 2015 Date of disclosure / English: March 24, 2015 German: http://www.equitystory.com/download/Companies/biotest/Annual%20Reports/EinzelabschlussBiotestAG2014.pdf English: ...

Further information
2015 AFR
23.02.2015

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

On February 20, 2015, Deka Investment GmbH, Frankfurt am Main, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, have fallen below the 3% threshold of the Voting Rights on February 18, 2015 and on that day amounted to 1.85% (this corresponds to 121716 Voting Rights). 1.85% of Voting Rights (this ...

Further information
2015 PVR
13.02.2015

Biotest AG: Biotest increases revenues significantly by 16.2%

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest increases revenues significantly by 16.2% Dreieich, 13. February 2015. According to preliminary and unaudited figures, the Biotest Group increased revenues to EUR 582.0 million. This represents an increase of 16.2% compared to the previous year (EUR 500.8 million). Biotest successfully gained ...

Further information
2015 ADHOC
09.02.2015

Biotest AG:

Biotest opens another plasma collection center in the US - Biotest continues strengthening global plasma collection with a second plasma  collection center in Jacksonville, North Caroline, USDreieich, February 9, 2015. Biotest announces that Biotest Pharmaceuticals Corporation (BPC), a 100% subsidiary of Biotest AG, Dreieich, has opened a new plasma collection center in ...

Further information
2015 CORPORATE
02.02.2015

Biotest AG: Publication according to § 26 paragraph. 1 WpHG with the objective of Europe-wide distribution

Universal-Investment-Gesellschaft mbH, 60486 Frankfurt, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, have fallen below the 3% threshold of the Voting Rights on January 23, 2015 and on that day amounted to 2.95% (this corresponds to 194702 Voting Rights). 2.95% of Voting Rights (this corresponds to ...

Further information
2015 PVR
09.12.2014

Biotest AG: Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone

Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone- New data from combination therapy study presented at 56th annual conference of the American Society of Hematology- Clinical benefit seen in all evaluable patients with advanced Multiple Myeloma- Complete remissions observed in individual patients- Good ...

Further information
2014 CORPORATE
18.11.2014

Biotest AG: Biotest Presents New Preclinical Data on Tregalizumab (BT-061) at the Annual

Biotest Presents New Preclinical Data on Tregalizumab (BT-061) at the Annual Meeting of the American College of Rheumatology in Boston - New preclinical results confirm treatment rationale in mono- and combination  therapy settings- Pro-inflammatory cytokines or methotrexate have no negative impact on in vitro  activation of regulatory T-cells by TregalizumabDreieich/ ...

Further information
2014 CORPORATE
17.11.2014

Biotest AG: Managers of Italian Subsidiary have been charged with illegal price fixing

Biotest: Managers of Italian Subsidiary have been charged with illegal price fixingDreieich, November 17, 2014. In 2010 the public prosecutor of Naples had initiated investigations against numerous employees of various pharmaceutical companies and institutions and charged them with illegal price fixing. Besides the Director of Administration of the University of Naples and the owner ...

Further information
2014 CORPORATE
12.11.2014

Biotest AG: Biotest increases sales by 11,5% compared to previous yea

Biotest increases sales by 11,5% compared to previous year- Good interim results of R&D projects Civacir(R) and Tregalizumab (BT-061)- Building permission for capacity expansion in Dreieich grantedDreieich, 12 November 2014. The Biotest Group was able to further increase its pace of growth recorded in the first half of the year in the first nine months of 2014. The Group ...

Further information
2014 CORPORATE
10.11.2014

Biotest AG: Very good results of Civacir(R) (Hepatitis C Immune Globulin) US Phase III clinical trial

Very good results of Civacir(R) (Hepatitis C Immune Globulin) US Phase III clinical trial - Preliminary data presented at the Congress of the American Association for the Study of Liver Disease (AASLD) show prevention of re-infection after liver-transplantation- More than 50% of study patients have been enrolled in the Civacir Phase III trial Dreieich, November 10, 2014. Biotest AG ...

Further information
2014 CORPORATE
05.11.2014

Biotest AG: Biotest receives marketing authorisation for Albiomin 20% in China

Biotest receives marketing authorisation for Albiomin 20% in China - Marketing approval granted for Albumin in China- The Chinese Pharmamarket is the second largest market for pharmaceuticalsDreieich, Germany, November 5 2014. Biotest has received the marketing authorization for Albiomin 20% (20% solution of human albumin) on October 31th, 2014 from the Chinese FDA (China Food and ...

Further information
2014 CORPORATE
24.10.2014

Biotest AG: Further preclinical studies emphasise the potential of Indatuximab Ravtansine (BT-062) in solid tumours

Further preclinical studies emphasise the potential of Indatuximab Ravtansine (BT-062) in solid tumours - Antibody-drug conjugate shows high efficacy in an animal model in the treatment of bladder, breast, pancreatic and other tumours. - Complete remission achieved in some treatment-refractory tumours. - Presentation of the results at the World ADC specialist conference in San ...

Further information
2014 CORPORATE
15.10.2014

Biotest AG: Search at Biotest - company rejects allegations

Search at Biotest - company rejects allegations- Accusations absolutely incomprehensible for Biotest AG- Proposal for clarification not accepted by public prosecutorDreieich, October 15, 2014. The Frankfurt Public Prosecution Office has once again executed a search at Biotest AG, Dreieich. The search is apparently based on the extension of the public prosecutions' investigation into ...

Further information
2014 CORPORATE
15.10.2014

Biotest AG: Search at Biotest - company rejects allegation

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Search at Biotest - company rejects allegations Dreieich, October 15, 2014. The Frankfurt Public Prosecution Office today once again executed a search at Biotest AG, Dreieich. The search is apparently based on the extension of the public prosecutors' investigations into the company's business with Russia, ...

Further information
2014 ADHOC
09.09.2014

Biotest AG: Biotest completes recruitment in Phase IIb study (TREAT 2b) of Tregalizumab (BT-061) in patients with rheumatoid arthritis

Biotest completes recruitment in Phase IIb study (TREAT 2b) of Tregalizumab (BT-061) in patients with rheumatoid arthritis - Biotest's largest and most complex clinical study is running according to plan - Patient recruitment completed. More than 300 patients enrolled within the past ten monthsDreieich, September 9, 2014. Biotest is pleased to announce that the last patient has ...

Further information
2014 CORPORATE
11.08.2014

Biotest AG: Outlook revised

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Outlook revised Dreieich, August 11, 2014. The Management Board revises its outlook. A sales increase of 7% and an operating result (EBIT) slightly above the previous year is expected. Prior to this, an increase of 10% was planned for both key figures. Main reasons for the lower outlook: The recall and the ...

Further information
2014 ADHOC
11.08.2014

Biotest AG: Biotest increases revenues by 8,5%

Biotest increases revenues by 8,5%- EBIT increase by 2,3%- Good Progress in the R&D pipeline- Revised outlookDreieich, August 11, 2014. The Biotest Group was again able to significantly increase revenues in the first half of 2014, recording growth of 8.5 % compared to the same period in the previous year. The Group generated revenues of EUR 264.1 million in the period under ...

Further information
2014 CORPORATE
09.07.2014

Biotest AG: Dr. Bernhard Ehmer to become new CEO of Biotest AG

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Dr. Bernhard Ehmer to become new CEO of Biotest AG Dreieich, 9 July 2014 - The Supervisory Board of Biotest AG, in its meeting today, has appointed Dr. Bernhard Ehmer (59) as member of the Executive Board effective November 1st, 2014. As of January 1st, 2015, Ehmer will take over the role as CEO from Prof. ...

Further information
2014 ADHOC
07.05.2014

Biotest AG: : Annual general meeting approves again increase of dividend

Biotest AG: Annual general meeting approves again increase of dividend- Distribution of EUR 0.57 per ordinary share and EUR 0.63 per preference shareDreieich/ Frankfurt a. M., 7 May 2014. At the annual general meeting (AGM) held on 7 May 2014 in Frankfurt am Main shareholders of Biotest AG approved a payment of an increased dividend. With 78.0 percent of the ordinary share capital ...

Further information
2014 CORPORATE
07.05.2014

Biotest AG: Biotest continues to show a sales increase

PRESS RELEASEBiotest continues to show a sales increase - Sales at EUR 122.2 million (+2.9%) - Progress in CapEx program "Biotest Next Level" - Positive development in R&D projectsDreieich,7 May 2014. The Biotest Group was again able to increase sales in the first three months of the 2014 financial year. The Group generated revenues of EUR 122.2 million in the period under review compared to ...

Further information
2014 CORPORATE
28.03.2014

Biotest AG: Correction of a release from March 27, 2014, 15:07 CET Publication according to § 26 paragraph. 1 WpHG with the objective of Europe-wide distribution

On March 26, 2014, Landkreis Biberach, Biberach, Deutschland has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Deutschland, have fallen below the 20% threshold of the Voting Rights on March 25, 2014 and on that day amounted to 19.95% (this corresponds to 1315780 Voting Rights). 19.95% of Voting Rights (this corresponds to ...

Further information
2014 PVR
27.03.2014

Biotest AG: Publication according to § 26 paragraph. 1 WpHG with the objective of Europe-wide distribution

On March 26, 2014, Landkreis Biberach, Biberach, Deutschland has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Deutschland, have fallen below the 20% threshold of the Voting Rights on March 25, 2014 and on that day amounted to 19.95% (this corresponds to 1315780 Voting Rights). 19.95% of Voting Rights (this corresponds to ...

Further information
2014 PVR
27.03.2014

Biotest AG: Biotest AG initiates clinical study with Indatuximab Ravtansine (BT-062) in solid tumors

Biotest AG initiates clinical study with Indatuximab Ravtansine (BT-062) in solid tumors- First patient treated in phase I/IIa study (no. 989) in patients with triple-negative metastatic breast cancer or metastatic urinary bladder cancerDreieich, 27 March 2014. Biotest AG, pursuing an innovative technology using the antibody-drug conjugate indatuximab ravtansine (BT-062) for ...

Further information
2014 CORPORATE
27.03.2014

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

On March 26, 2014, Kreissparkasse Biberach, Biberach, Deutschland has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Deutschland, have fallen below the 20% threshold of the Voting Rights on March 25, 2014 and on that day amounted to 19.95% (this corresponds to 1315780 Voting Rights). 27.03.2014 DGAP's Distribution ...

Further information
2014 PVR
25.03.2014

Biotest AG: Biotest increases profit after tax by 38.5 %

Biotest increases profit after tax by 38.5 %- Earnings before interest and tax (EBIT) of the Biotest Group at EUR53.8 million represents an increase of 20.4 % vs. the previous year- Revenue increase by 13.8 % Dreieich, 25 March 2014. In the 2013 financial year Biotest was again able to increase sales significantly by 13.8 % and exceeded the EUR 500 million mark for the first time. ...

Further information
2014 CORPORATE
20.02.2014

Biotest AG: Biotest increases earnings after taxes by 38.5%

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest increases earnings after taxes by 38.5% Dreieich, 20. February 2014. According to preliminary and unaudited figures, the Biotest Group recorded earnings after tax (EAT) of EUR 32.0 million, an increase from EUR 23.1 million in 2012 by 38.5%. Earnings before taxes (EBT) increased by 31.0% to EUR 47.8 ...

Further information
2014 ADHOC
20.12.2013

Biotest AG: Biotest receives marketing authorisation for Albiomin(R) in Brazil and approval for commissioning of expanded albumin production

Biotest receives marketing authorisation for Albiomin(R) in Brazil and approval for commissioning of expanded albumin production- Marketing approval granted for albumin in Brazil- Albumin production capacity doubled from 21 to 42 tons in Dreieich, GermanyDreieich, Germany, 20 December 2013. Biotest Farmaceutica Ltda., Brazil, a 100% subsidiary of Biotest AG, has announced that it ...

Further information
2013 CORPORATE
10.12.2013

Biotest AG: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone

Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone. - Efficacy and tolerability data from combination therapy study 983 presented at 55th annual conference of the American Society of Hematology (ASH) - Good tolerability of combination therapy with indatuximab ...

Further information
2013 CORPORATE
03.12.2013

Biotest AG: Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A

Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia ADreieich/ Germany, Rhode Island/ USA, 3 December 2013. Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The ...

Further information
2013 CORPORATE
20.11.2013

Biotest AG: Biotest Pharmaceuticals Honoured with the 2013 Greater Miami Chamber of Commerce International Business Leadership Award for 'Business Expansion'

Biotest Pharmaceuticals Honoured with the 2013 Greater Miami Chamber of Commerce International Business Leadership Award for 'Business Expansion' Boca Raton, FL, US/ Dreieich, Germany, November 20, 2013 - Biotest Pharmaceuticals Corporation (BPC), a wholly owned US subsidiary of Biotest AG, (Dreieich Germany), announced yesterday that it has been awarded the 2013 International ...

Further information
2013 CORPORATE
12.11.2013

Biotest AG: Biotest increases guidance significanty

Biotest increases guidance significanty- Increase of earnings before tax (EBT) by 41.2%- EBIT increase by 21.6%- Successful placement of a privately placed promissory note (Schuldschein) of EUR 210 million equivalent in the capital marketDreieich, 12 November 2013. The Biotest Group increased sales by 13.1 % in the first nine months of 2013 compared to the same period in the ...

Further information
2013 CORPORATE
12.11.2013

Biotest AG: Managing Board increases guidance 2013

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Managing Board increases guidance 2013 Dreieich, 12 November 2013. The Managing Board of Biotest AG significantly raised the company's forecast for profit before interest and tax (EBIT) in the current year. The Management now expects a sales increase of 10% - 15% and an EBIT increase of 15% - 20%. Until now ...

Further information
2013 ADHOC
28.10.2013

Biotest AG: Biotest presents the results of a Phase II study of tregalizumab (BT-061) at the American College of Rheumatology (ACR) Annual Meeting in San Diego

/Biotest presents the results of a Phase II study of tregalizumab (BT-061) at the American College of Rheumatology (ACR) Annual Meeting in San Diego - Good Efficacy and safety data of previous trials confirmed - The study protocol of a new Phase IIb study (TREAT 2b) has been approved in several countriesDreieich/ Germany, October 28, 2013. Biotest AG today announced the presentation of efficacy ...

Further information
2013 CORPORATE
24.10.2013

Biotest AG: Biotest AG successfully placed a Schuldschein of EUR 210 m.

Biotest AG successfully placed a Schuldschein of EUR 210 m.- Three times oversubscribed due to the significant investor demand - Further milestone for the financing of the company growth strategy achieved Dreiech, October 24, 2013 - Biotest successfully placed a Schuldschein of approx. EUR 210 m. Commerzbank Aktiengesellschaft and Landesbank Hessen-Thüringen (Helaba) acted as ...

Further information
2013 CORPORATE
15.10.2013

Biotest AG: Biotest supports the 'Project Recovery' in turning unused blood products from Canadian blood donations into hemophilia medicine for developing countries

Biotest supports the 'Project Recovery' in turning unused blood products from Canadian blood donations into hemophilia medicine for developing countries - This project will enable the WFH (World Federation of Hemophila) to improve its Humanitarian Aid Program - Biotest to manufacture Haemoctin(R) in Dreieich, Germany Dreieich/ Montreal, October 15, 2013 - The World Federation of ...

Further information
2013 CORPORATE
11.10.2013

Biotest AG: Biotest AG opens three further plasmapheresis centers in Hungary and the USA

Biotest AG opens three further plasmapheresis centers in Hungary and the USA - Inauguration opening of new collection center in Budapest marks doubling of capacities in Hungary - Two new centers already opened in USA in 2013, with two additional centers to follow in FloridaDreieich, October 11, 2013 - Today, Biotest is celebrating the opening of its second plasmapheresis center in ...

Further information
2013 CORPORATE
13.08.2013

Biotest AG: Biotest increases earnings after tax by 55%

PRESS RELEASEBiotest increases earnings after tax by 55% - New sales record in second quarter 2013 - Capital increase very successfully completed - Confirmation of Guidance of sales and EBIT growth of 10 - 15% in 2013Dreieich, 13 August 2013. The Biotest Group achieved record sales in the first six months of 2013 and is still on its projected growth path. In the reporting period the Group ...

Further information
2013 CORPORATE
05.08.2013

Biotest AG: First patient treated with CivacirTM after Hepatitis C induced liver transplantation in Biotest's Phase III clinical trial

PRESS RELEASEFirst patient treated with CivacirTM after Hepatitis C induced liver transplantation in Biotest's Phase III clinical trial - 50% of liver transplantations are due to Hepatitis C infection - High unmet medical need: Prevention of Hepatitis C virus recurrence in liver transplant - CivacirTM has an orphan drug designation in both the US and the EU Dreieich, 05 August 2013. Biotest AG ...

Further information
2013 CORPORATE
26.06.2013

Biotest AG: Biotest AG successfully completes capital increase 2013: New shares were oversubscribed, Issuing volume amounts to EUR 76 million

Biotest AG successfully completes capital increase 2013: New shares were oversubscribed, Issuing volume amounts to EUR 76 millionDreieich, June 26, 2013 - During this year's annual shareholders meeting of Biotest AG, chief executive officer Professor Dr. Gregor Schulz announced a capital increase to finance the company's expansion strategy. Today Biotest announces the successful ...

Further information
2013 CORPORATE
10.06.2013

Biotest AG: Biotest AG sets the subscription price and the offer price for the new preferred shares at EUR 52.00 per preferred share

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG sets the subscription price and the offer price for the new preferred shares at EUR 52.00 per preferred share Dreieich, 10 June 2013 - The management board of Biotest AG decided today, in consultation with equinet Bank AG, on the further parameters for the capital increase against cash ...

Further information
2013 ADHOC
10.06.2013

Biotest AG: Biotest AG has resolved to utilise its authorised capital with subscription rights for existing shareholders

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG has resolved to utilise its authorised capital with subscription rights for existing shareholders Dreieich, 10 June 2013 - The management board and supervisory board of Biotest AG have resolved today to increase the share capital of Biotest AG (the 'Company') from EUR 30,025,152.00 by up to EUR ...

Further information
2013 ADHOC
08.05.2013

Biotest AG: Biotest AG: Annual general meeting approves increase of dividend

Biotest AG: Annual general meeting approves increase of dividend - Distribution of EUR 0.50 per ordinary share and EUR 0.56 per preference shareDreieich / Frankfurt a. M., 8 May 2013. At the annual general meeting (AGM) held on 8 May 2013 in Frankfurt am Main shareholders of Biotest AG approved payment of an increased dividend. With 82,4 percent of the ordinary share capital ...

Further information
2013 CORPORATE
08.05.2013

Biotest AG: Biotest AG plans a capital increase and rights issue

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG plans a capital increase and rights issue Dreieich, 8 May 2013 - Today, Management Board and Supervisory Board of Biotest AG have resolved on a planned capital increase from authorised capital against cash contributions. Biotest AG plans to increase its share capital from EUR 30,025,152.00 by ...

Further information
2013 ADHOC
08.05.2013

Biotest AG: Biotest Group reports increase of EBIT

PRESS RELEASEBiotest Group reports increase of EBIT - EBIT up 13.5% at EUR 11.8 million - Sales increased to EUR 118.7 million - Management Board confirms guidanceDreieich, 8 May 2013. In the first three months of financial year 2013 the Biotest Group was able to significantly increase sales again and achieve a new quarterly sales record. In the reporting period the Group generated revenues of ...

Further information
2013 CORPORATE
25.03.2013

Biotest AG: Biotest increases Profit before Tax by 28%

Biotest increases Profit before Tax by 28% - Profit after tax of the Biotest Group (Continuing Operations) at EUR23.1 million represents an increase of 23.5% vs. the previous year - Revenue increase by 4.3% Dreieich, 25 March 2013. In 2012 the Biotest Group has increased the profit after tax of the Continuing Operations by 23.5% compared to the previous year, the profit before tax ...

Further information
2013 CORPORATE
21.03.2013

Biotest AG: Biotest decides to move into biggest Phase IIb trial in company history

Biotest decides to move into biggest Phase IIb trial in company historyDreieich, 21 March 2013. Biotest announced today that Biotest intends to start an additional Phase IIb trial with up to 350 patients with Tregalizumab (BT-061), a monoclonal antibody in development for the treatment of Rheumatoid Arthritis. Tregalizumab, which activates regulatory T-cells of the patient's immune ...

Further information
2013 CORPORATE
21.02.2013

Biotest AG: Biotest increases earnings before taxes by 28%

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest increases earnings before taxes by 28% Dreieich, 21. February 2013. According to preliminary and unaudited figures, the Biotest Group recorded Earnings before taxes (EBT) of EUR 36.5 million for its Continuing Operations (previous year result EUR 28.6 million). The main factors for this profit ...

Further information
2013 ADHOC
04.02.2013

Biotest AG: Biotest announces launch of BIVIGAM(TM)in the United States

Biotest announces launch of BIVIGAM(TM)in the United StatesDreieich, February 4, 2013 - Biotest announces the launch of BIVIGAM(TM) in the US market. BIVIGAM(TM) is a human intravenous immune globulin 10% liquid, which will be distributed by Biotest Pharmaceuticals Corporation (BPC) a wholly owned U.S. subsidiary of Biotest AG. The product is now available on a regular basis for ...

Further information
2013 CORPORATE
22.01.2013

Biotest AG: Increase in Earnings after Tex for Fiscal Year 2012

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Dreieich, 22 January 2013. Biotest AG announces that earnings after tax for the year 2012 will increase by approx. EUR 10 million. (This additional income will be reported in earnings after tax from Discontinued Operation.) This income results from the sale of the former segment Microbiological Monitoring. At ...

Further information
2013 ADHOC
21.01.2013

Biotest AG: Biotest AG with new sales and distribution activities in Russia and Greece

PRESS RELEASEBiotest AG with new sales and distribution activities in Russia and Greece - Biotest AG concentrates its sales activities on Russian market through cooperation with Merz Pharma GmbH & Co. KGaA - Transfer of Distribution Rights in Greece from Biotest AG to Vianex s.a.Dreieich, January 21, 2013. Biotest is aiming to further expand its already strong position on the Russian market ...

Further information
2013 CORPORATE
16.01.2013

Biotest AG: Biotest Announces Strategic Long-Term Manufacturing, Supply and License Agreement

Biotest Announces Strategic Long-Term Manufacturing, Supply and License Agreement - Manufacturing & Supply agreement - License agreement for ADMA's Respiratory Syncytial Virus IGIV product candidate for EU and selected countriesDreieich/ Boca Raton, January 16, 2013 - Biotest announces, that Biotest Pharmaceuticals Corp. (BPC), a wholly owned U.S. subsidiary of Biotest AG ...

Further information
2013 CORPORATE
09.01.2013

Biotest AG: Biotest AG's Supervisory Board extends the term of CEO Prof. Schulz and appoints Dr. Floß to the Board of Management

Further information
2013 CORPORATE
20.12.2012

Biotest AG: FDA Approves Bivigam TM

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Dreieich, Germany and Boca Raton, Florida December 20, 2012: Biotest AG announced today that Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of the listed Biotest AG, received approval for BIVIGAM(TM) for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food ...

Further information
2012 ADHOC
20.12.2012

Biotest AG: FDA Approves Biotest's BIVIGAM(TM), an Intravenous Immune Globulin (Human), 10% liquid

FDA Approves Biotest's BIVIGAM(TM), an Intravenous Immune Globulin (Human), 10% liquidDreieich, Germany and Boca Raton, Florida December 20 2012: Biotest AG announced today that Biotest Pharmaceuticals Corporation received approval for Bivigam(TM) for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food and Drug Administration (FDA) yesterday ...

Further information
2012 CORPORATE
13.12.2012

Biotest AG: Biotest with new management team for research and regulatory affairs

PRESS RELEASEBiotest with new management team for research and regulatory affairs - Dr. Jörg Schüttrumpf takes over responsibility for pre-clinical research and development as new Head of Global Research - Experienced physician and pharmaceutical manager Prof. Dr. Markus Rothenburger is assuming the position as Head of Medical/ Regulatory Affairs at the beginning of next yearDreieich, December ...

Further information
2012 CORPORATE
11.12.2012

Biotest AG: Biotest AG signs strategically significant agreement to market human albumin in China

Biotest AG signs strategically significant agreement to market human albumin in China - Access to fast growing, high-price Chinese albumin market - Revenue of EUR 20 to EUR 30 million expected in medium term - Strong sales and distribution partner Wanbang Biopharma, a Fosun Pharma Group company, as guarantee for successDreieich, December 11, 2012. By signing the long-term ...

Further information
2012 CORPORATE
06.12.2012

Biotest AG: Biotest starts clinical development programme of human fibrinogen concentrate to treat serious, life-threatening bleeding

Biotest starts clinical development programme of human fibrinogen concentrate to treat serious, life-threatening bleeding - Approval of study protocol to conduct a phase I/II clinical trial - Treatment of first patient with congenital fibrinogen deficiency is expected shortlyDreieich, 6. December 2012. After approval of the study protocol Biotest will start clinical development of ...

Further information
2012 CORPORATE
13.11.2012

Biotest AG: Biotest increases EBT by 26%

Biotest increases EBT significantly by 26% - EBIT increase by 9.0% - BivigamTM - 'Complete Response Letter' sent to FDA - Long term Agreement closed with ViroPharma, USADreieich, 13. November 2012. During the first nine months of 2012, the Biotest Group was able to increase its revenue by 4.2% compared with sales from Continuing Operations in the same period of 2011. Thus, the ...

Further information
2012 CORPORATE
24.10.2012

Biotest AG: Biotest AG expands existing product portfolio with the marketing authorisation of Intratect 100 g/l (10%)

PRESS RELEASEBiotest AG expands existing product portfolio with the marketing authorisation of Intratect 100 g/l (10%) - Marketing authorisation of Intratect 100 g/l (10%) under the European Decentralised Procedure - Marketing of the new product possible in 18 other European countries in addition to Germany - Market introduction in Germany expected from January 2013Dreieich, 24. October 2012. ...

Further information
2012 CORPORATE
13.08.2012

Biotest AG: Biotest Group with double digit EBIT growth

PRESS RELEASEBiotest Group with double digit EBIT growth - Sales increase to EUR 220.2 mio. - EBIT increase by 14.5% to EUR 22.9 EUR mio. - Management confirms guidance 2012Dreieich, 13 August 2012. The Biotest Group was once again able to increase revenues in the first half of 2012 compared with sales from continuing operations in the same period of 2011. Revenues in the first six months of ...

Further information
2012 CORPORATE
07.08.2012

Biotest AG: Clinical Data on Efficacy and Safety of Bivigam(TM) accepted by FDA. Sales and profit guidance confirmed despite delays in US registration.

Clinical Data on Efficacy and Safety of BivigamTM accepted by FDA. Sales and profit guidance confirmed despite delays in US registration. Dreieich, Germany, 7 August 2012: In an official statement by the United States Food and Drug Administration, FDA, received on August 6, 2012 no questions were raised on the clinical efficacy and safety of the newly developed investigational ...

Further information
2012 CORPORATE
16.07.2012

Biotest AG: Biotest AG starts combination therapy study with BT-062 in multiple myeloma

Biotest AG starts combination therapy study with BT-062 in multiple myeloma - Antibody-drug conjugate BT-062 continues to show good tolerability in monotherapy - First patient treated in phase I/IIa combination therapy study (no. 983) in multiple myeloma - Funding for further activities in solid tumours approved by excellence cluster CI3 Rhine-Main 'Individualized ...

Further information
2012 CORPORATE
10.05.2012

Biotest AG: Biotest Group reports substantially higher EBIT

Biotest Group reports substantially higher EBIT - EBIT up 14.3% at EUR 10.4 million - Sales increased to EUR 107.7 million - Management Board confirms forecastDreieich, 10 May 2012. The Biotest Group has increased its earnings before interest and taxes (EBIT) in the first three months of the 2012 financial year by a substantial 14.3%. The company generated earnings of EUR 10.4 ...

Further information
2012 CORPORATE
10.05.2012

Biotest AG: Annual general meeting approves dividend

PRESS RELEASEBiotest AG: Annual general meeting approves dividend - Distribution of EUR 0.44 per ordinary share and EUR 0.50 per preference share - Dr. Alessandro Banchi elected as new Supervisory Board ChairmanDreieich / Frankfurt a. M., 10 May 2012. At the annual general meeting (AGM) held on 10 May 2012 in Frankfurt am Main shareholders of Biotest AG approved payment of a dividend. With ...

Further information
2012 CORPORATE
08.05.2012

Biotest AG: Preliminary investigation by public prosecution - Company rejects suspicions

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Preliminary investigation by public prosecution - Company rejects suspicions Dreieich, May 8, 2012 - The Frankfurt public prosecutor today initiated a preliminary investigation at Biotest AG, Dreieich. This is based on an anonymous allegation against several persons which accuses also employees of Biotest ...

Further information
2012 ADHOC
23.04.2012

Biotest consolidates its outstanding position in the hepatitis B hyperimmunoglobulin market with the marketing authorisation of Fovepta and with the initial sales of Hepatect(R) in Brazil

Biotest consolidates its outstanding position in the hepatitis B hyperimmunoglobulin market with the marketing authorisation of Fovepta and with the initial sales of Hepatect(R) in Brazil - Marketing authorisation of Fovepta(R) in Germany - Initial sales of Hepatect(R) in Brazil - Continuation of the clinical development of Civacir(TM) planned for the second half of ...

Further information
2012 CORPORATE
11.04.2012

Biotest AG: Biotest announces clinical trial data for its new investigational Intravenous Immunoglobulin (IVIG) product for the US market

Biotest announces clinical trial data for its new investigational Intravenous Immunoglobulin (IVIG) product for the US marketDreieich, 11 April 2012. Biotest AG announces the publication of its US subsidiary Biotest Pharmaceuticals Corporation (BPC), Boca Raton, Florida, USA of Wasserman et al.,:'Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin ...

Further information
2012 CORPORATE
22.03.2012

Biotest AG: BT-062 demonstrates rapid and complete tumor eradication in preclinical studies

PRESS RELEASEBT-062 demonstrates rapid and complete tumor eradication in preclinical studies - Pronounced anti-tumor activity against aggressive solid tumors, e.g. human breast, pancreas, bladder and lung cancers in preclinical studies - Data show efficacy in indications with a particularly high medical need - Project proposal selected for application to center of excellence cluster CI3, an ...

Further information
2012 CORPORATE
22.03.2012

Biotest AG: Biotest reached an all-time high Profit after Tax

Biotest reached an all-time high Profit after Tax - Profit after tax of the Biotest Group (Continuing Operations and Discontinued Operation) at EUR48.1 million represents an increase of 21.8% vs. the previous year - Profit after tax contribution of EUR26.4 million from sale of Microbiological Monitoring - Revenue increase by 2.3% Dreieich, 22 March 2012. In 2011 the Biotest Group ...

Further information
2012 CORPORATE
15.03.2012

Biotest AG: Correction of the Publication according to § 26 paragraph. 1 WpHG from February 22, 2012 with the objective of Europe-wide distribution

Notification of voting rights pursuant to sec. 41 para. 4d WpHG We received the following notification pursuant to sec. 41 para. 4d WpHG on February 22, 2012: 1. Listed company: Biotest AG Landsteinerstraße 5, 63303 Dreieich, Deutschland 2. Notifier: Ms Renate Scheussner, Deutschland 3. Total amount of voting rights held on February 1st, 2012: 50,27% (equals 3315508 voting ...

Further information
2012 PVR
15.03.2012

Biotest AG: Correction of a Publication according to § 26 paragraph. 1 WpHG from February 22, 2012 with the objective of Europe-wide distribution

Notification of voting rights pursuant to sec. 41 para. 4d WpHG We received the following notification pursuant to sec. 41 para. 4d WpHG on February 22, 2012: 1. Listed company: Biotest AG Landsteinerstraße 5, 63303 Dreieich, Deutschland 2. Notifier: Mr Martin Dr. Schleussner, Deutschland 3. Total amount of voting rights held on February 1st, 2012: 50,27% (equals 3315508 voting ...

Further information
2012 PVR
15.03.2012

Biotest AG: Correction of a Publication according to § 26 paragraph. 1 WpHG from February 22, 2012 with the objective of Europe-wide distribution

Notification of voting rights pursuant to sec. 41 para. 4d WpHG We received the following notification pursuant to sec. 41 para. 4d WpHG on February 22, 2012: 1. Listed company: Biotest AG Landsteinerstraße 5, 63303 Dreieich, Deutschland 2. Notifier: Mr Hans Dr. Schleussner, Deutschland 3. Total amount of voting rights held on February 1st, 2012: 50,27% (equals 3315508 voting ...

Further information
2012 PVR
22.02.2012

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of voting rights pursuant to sec. 41 para. 4d WpHG We received the following notification pursuant to sec. 41 para. 4d WpHG on February 22, 2012: 1. Listed company: Biotest AG Landsteinerstraße 5, 63303 Dreieich, Deutschland 2. Notifier: Mr Martin Dr. Schleussner, Deutschland 3. Total amount of voting rights held on February 1st, 2012: 50,27% (equals 3315508 voting ...

Further information
2012 PVR
22.02.2012

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of voting rights pursuant to sec. 41 para. 4d WpHG We received the following notification pursuant to sec. 41 para. 4d WpHG on February 22, 2012: 1. Listed company: Biotest AG Landsteinerstraße 5, 63303 Dreieich, Deutschland 2. Notifier: Ms Renate Schleussner, Deutschland 3. Total amount of voting rights held on February 1st, 2012: 50,27% (equals 3315508 voting ...

Further information
2012 PVR
22.02.2012

Biotest AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Notification of voting rights pursuant to sec. 41 para. 4d WpHG We received the following notification pursuant to sec. 41 para. 4d WpHG on February 22, 2012: 1. Listed company: Biotest AG Landsteinerstraße 5, 63303 Dreieich, Deutschland 2. Notifier: Mr Hans Dr. Schleussner, Deutschland 3. Total amount of voting rights held on February 1st, 2012: 50,27% (equals 3315508 voting ...

Further information
2012 PVR
20.02.2012

Biotest AG: Slight increase in sales of 2.3% despite difficult market environment

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest: Slight increase in sales of 2.3% despite difficult market environment Dreieich, 20 February 2012. According to preliminary and unaudited figures, the Biotest Group (Plasma Proteins and Biotherapeutics) recorded sales of EUR 422.0 million in the financial year 2011, an increase of 2.3% compared to ...

Further information
2012 ADHOC
09.02.2012

Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 22, 2012 German: http://www.equitystory.com/download/Companies/biotest/Annual%20Reports/Biotest_Einzelabschluss2011.pdf Report: Annual financial report of the group Date of disclosure / German: March 22, 2012 Date of disclosure / English: ...

Further information
2012 AFR
12.12.2011

Biotest AG: Clinical development of BT-062 in multiple myeloma expands into combination therapy

Clinical development of BT-062 in multiple myeloma expands into combination therapy  Efficacy and tolerability data from monotherapy studies 969 and 975 presented at 53rd annual conference of the American Society of Hematology  Clinical benefit already seen in more than 50 % of patients receiving repeat single-dose regimen  Good tolerability confirmed with multi-dose regimen at ...

Further information
2011 CORPORATE
24.11.2011

Biotest AG: Tregalizumab (BT-061) shows efficacy in Chronic Plaque Psoriasis

Tregalizumab (BT-061) shows efficacy in Chronic Plaque Psoriasis  Final results of the first repeated dose phase II trial in Chronic Plaque Psoriasis show efficacy in the higher subcutaneous dose groups  Good tolerability confirmed  Further development in Psoriasis will be based on results of larger clinical trials in Rheumatoid Arthritis Dreieich, 24 November 2011. In its ...

Further information
2011 CORPORATE
10.11.2011

Biotest AG: Biotest: Significant Increase in Profit after Tax

Biotest: Significant Increase in Profit after Tax - Increase of Profit after tax by 31.1% (Continuing and Discontinued Operations) - Profit after tax contribution of EUR 22 million from sale of Microbiological Monitoring - Increase of Profit after tax by 14.1% (Continuing Operations) - Revenue increase by 1.9% Dreieich, 10 November 2011. In the first nine months of 2011 the ...

Further information
2011 CORPORATE
11.08.2011

Biotest AG: First time Revenue and EBIT contribution by Biotherapeutics Segment; continuing difficult Plasma Protein Product Environment

First time Revenue and EBIT contribution by Biotherapeutics Segment; continuing difficult Plasma Protein Product Environment - Sales increased by 4,9 % in first half of 2011 in continuing operations - Earnings situation burdened by market environment and unabsorbed costs in the US - Global Development and Cooperation contract with Abbott for BT 061 Dreieich, 11 August 2011. The Biotest ...

Further information
2011 CORPORATE
01.08.2011

Biotest AG: Sale of Microbiological Monitoring business to Merck KGaA completed

Sale of Microbiological Monitoring business to Merck KGaA completed - Transaction has been successfully closed today after clearance of merger control authorities was given - Biotest focusses now on Plasmaproteins and Biotherapeutics Dreieich, 1st August, 2011. All relevant merger control authorities approved the sale of Biotest's AG woldwide activities of its Microbiological Monitoring ...

Further information
2011 CORPORATE
22.06.2011

Biotest AG: Pentaglobin(R) shows high binding capacity against the current EHEC strain and its Shiga-like toxin 2

22.06.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and ...

Further information
2011 CORPORATE
21.06.2011

Biotest AG: Abbott and Biotest Announce Global Agreement to Development and Commercialize Novel Antibody for Autoimmune Diseases

21.06.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and ...

Further information
2011 CORPORATE
21.06.2011

Biotest AG: Agreement with Abbott

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Dreieich, June 21, 2011 - Abbott and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently in Phase II clinical trials for RA and psoriasis, with preclinical studies underway ...

Further information
2011 ADHOC
12.05.2011

Biotest AG: Biotest AG: Annual General Meeting approves dividend increase

12.05.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and ...

Further information
2011 CORPORATE
10.05.2011

Biotest AG: Sales increase in the first quarter

10.05.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and ...

Further information
2011 CORPORATE
28.04.2011

Biotest AG: Ad hoc ANNOUNCEMENT

Ad hoc ANNOUNCEMENT Announcement in accordance with Section 15 (1) of the German Securities Trading Act (WpHG) Dreieich, 28 April 2011. The Board of Management of Biotest AG has adjusted its 2011 earnings targets for the Continuing Operations of the Biotest Group but affirmed its sales goal. This is due to events at the subsidiary Biotest Pharmaceuticals Corporation (BPC), Boca Raton, USA, ...

Further information
2011 ADHOC
22.03.2011

Biotest AG: Sales increase despite difficult market environment

22.03.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and ...

Further information
2011 CORPORATE
22.03.2011

Biotest AG: Biotest: Monoclonal antibody BT-061 in combination with methotrexate demonstrates good efficacy in Rheumatoid Arthritis

22.03.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and ...

Further information
2011 CORPORATE
22.03.2011

Biotest AG: Ad-hoc RELEASE Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Dreieich, March 22, 2011. Biotest AG has signed tonight a contract today to sell its woldwide activities of its Microbiological Monitoring business, consisting of the product portfolio of HYCON (hygiene monitoring) and the product portfolio of heipha Dr. Müller GmbH (microbiological culture media and ...

Further information
2011 ADHOC
25.02.2011

Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 22, 2011 German: http://irpages.equitystory.com/download/Companies/biotest/Annual%20Reports/Biotest_Einzelabschluss2010.pdf Report: Annual financial report of the group Date of disclosure / German: March 22, 2011 Date of disclosure / ...

Further information
2011 AFR
15.02.2011

Biotest AG: Increase in sales of more than 5%

Biotest: Increase in sales of more than 5% Dreieich, 15 February 2011. According to preliminary and unaudited figures, the Biotest Group (Plasma Proteins and Microbiological Monitoring) recorded sales of EUR 461.2 million in the financial year 2010, an increase of 5.2% compared to the previous year (EUR 438.6 million). Earnings before interest and tax (EBIT) of the Group (Plasma ...

Further information
2011 ADHOC
27.01.2011

Biotest AG: Interim analysis of the Cytotect(R) Phase III trial in congenital cytomegalovirus (CMV) infection shows clear indication of efficacy

27.01.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and ...

Further information
2011 CORPORATE
19.01.2011

Biotest AG: Biotest erwirbt Vertriebsgesellschaft in Brasilien

19.01.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and ...

Further information
2011 CORPORATE
06.12.2010

Biotest AG: Clinical and pre-clinical data emphasise the potential of

Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Deutschland Phone: 0 61 03 - 8 ...

Further information
2010 CORPORATE
17.11.2010

Biotest AG: Biotest: Pre-clinical studies demonstrate high efficacy of BT-062 in solid tumours

Biotest: Pre-clinical studies demonstrate high efficacy of BT-062 in solid tumours  Immunoconjugate induces complete remission of human solid tumours in mouse models  High anti-tumour activity against aggressive human breast, pancreas, bladder and lung carcinoma  Data show efficacy in indications with a particularly great medical need Dreieich, Germany, 17 November 2010. Today ...

Further information
2010 CORPORATE
08.11.2010

Biotest AG: Biotest experiences sales growth

Biotest experiences sales growth  Sales after nine months 3.5% above the previous year  Performance continues to be affected by the difficult market environment  Board of Management confirms projections for the year as a whole Dreieich, 8 November 2010. In the first nine months of financial year 2010, the Biotest Group recorded sales of EUR342.3 million in its Continuing Operations, ...

Further information
2010 CORPORATE
03.11.2010

Biotest AG: Biotest submits BivigamTM dossier for regulatory approval to US Food and Drug Administration

Biotest submits BivigamTM dossier for regulatory approval to US Food and Drug Administration  Important step to expand US market position  Annual sales potential of around USD 100 Mio.  Biotest expects approval for end of 2011 Dreieich, 3 November 2010. Biotest Pharmaceutiocals Corp., Boca Raton/ USA has submitted today the dossier for regulatory approval of the ...

Further information
2010 CORPORATE
21.10.2010

Biotest AG: Monoclonal antibody BT-061 shows potential in the indication multiple sclerosis

Monoclonal antibody BT-061 shows potential in the indication multiple sclerosis - Biotest generates positive pre-clinical data in the indication multiple sclerosis - Further development in this indication supported by the German Federal Ministry of Education and Research in the framework of the 'Neu² Konsortium' Dreieich, 21. October 2010. Biotest has obtained positive ...

Further information
2010 CORPORATE
12.08.2010

Biotest AG: Positive perspective despite difficult environment

Positive perspective despite difficult environment - Final results for first half of 2010: sales increased by 4 % - Earnings situation burdened by market environment - Important progress in R&D projects achieved Dreieich, 12 August 2010. The Biotest Group presented its half-year report as of 30 June 2010 today. The Group recorded a slight revenue increase of 4% in the first half of 2010, ...

Further information
2010 CORPORATE
11.08.2010

Biotest AG: Development of BT-062 makes further progress with start of a new clinical trial

Biotest: Development of BT-062 makes further progress with start of a new clinical trial - Phase I clinical study completes patient recruitment - Encouraging results concerning efficacy and tolerability - Phase I/IIa clinical trial in multiple myeloma has started Dreieich, Germany, 11. August 2010. Biotest AG is pursuing an innovative therapeutic strategy to treat multiple myeloma using the ...

Further information
2010 CORPORATE
10.08.2010

Biotest AG: Immunomodulatory antibody BT-061 shows competitive efficacy in the indication Rheumatoid Arthritis

Immunomodulatory antibody BT-061 shows competitive efficacy in the indication Rheumatoid Arthritis - Phase IIa monotherapy trial completed - Competitive clinical efficacy already after a short treatment period - Good safety and tolerability profile confirmed Dreieich, Germany, 10. August 2010. Biotest AG is pleased to announce final data from a phase IIa clinical trial with its ...

Further information
2010 CORPORATE
10.08.2010

Biotest AG: BT-061 patent protection significantly expanded

Biotest: BT-061 patent protection significantly expanded - Compound patent granted in most important pharma markets - Valuable asset for future partnerships Dreieich, Germany, 10. August 2010. Biotest AG, a provider of pharmaceutical and biotherapeutic drugs for immunological and haematological diseases, announced today that a key patent for its unique monoclonal antibody drug candidate ...

Further information
2010 CORPORATE
14.07.2010

Biotest AG: Biotest increases sales despite greater financial pressure

Biotest increases sales despite greater financial pressure - In the first half of 2010, sales up 4.0% on the previous year at EUR 227.1 million - Market environment and government savings package impact earnings - Board of Management scales down expectations for the full year 2010 Dreieich, Germany, 14 July 2010. Today, the Biotest Group issued an ad hoc announcement containing ...

Further information
2010 CORPORATE
14.07.2010

Biotest AG: Preliminary Results

Dreieich, Germany, 14 July 2010. According to preliminary figures, the Biotest Group recorded a slight revenue increase of 4% in the first half of 2010, taking sales to EUR227.1 million (first half of 2009: EUR218.4 million). The Group generated earnings before interest and taxes (EBIT) of EUR23.7 million (previous year: EUR31.2 million. Earnings fell short of the Company's expectations, ...

Further information
2010 ADHOC
11.05.2010

Biotest AG: Biotest shows sales growth in first quarter 2010 despite a difficult environment

Biotest shows sales growth in first quarter 2010 despite a difficult environment - Q1 2010: Revenue Growth of 5.2 % and EBIT decrease due to high R&D expenses as well as price declines - Earnings after tax nearly tripled to EUR 22.6 million due to extraordinary income from the sale of Medical Diagnostics - Outlook 2010 confirmed Dreieich, May 11, 2010. Sales in the first quarter 2010 ...

Further information
2010 CORPORATE
06.05.2010

Biotest AG: Biotest has recorded sales growth in first quarter 2010 despite a difficult environment

Biotest has recorded sales growth in first quarter 2010 despite a difficult environment - Q1 2010: Revenue Growth of 5,2 % and EBIT decrease of 18,0 %; Earnings after Tax nearly tripled due to extraordinary income from the sale of Medical Diagnostics - Outlook 2010 confirmed Dreieich/ Frankfurt am Main, May 6, 2010 - In his speech at the Annual Shareholder's Meeting today, the Chairman ...

Further information
2010 CORPORATE
06.05.2010

Biotest AG: Annual General Meeting 2010: Shareholders Approve Dividend of EUR 0.34 per Ordinary Share and EUR 0.40 per Preference Share

Annual General Meeting 2010: Shareholders Approve Dividend of EUR 0.34 per Ordinary Share and EUR 0.40 per Preference Share Dreieich/ Frankfurt am Main, May 6, 2010 - Shareholders of Biotest AG with 81.7% of shareholder present, approved a dividend of EUR 0.34 per ordinary share for 2009 and a dividend of EUR 0.40 per preference share at the company's Annual General Meeting held today in ...

Further information
2010 CORPORATE
22.03.2010

Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

This is an announcement of change. Biotest AG hereby announces that the following financial reports shall be disclosed: Report: Financial report of the group (half-year) Date of disclosure / German: August 12, 2010 Date of disclosure / English: August 12, 2010 German: http://www.equitystory.com/download/companies/biotest/Quarterly%20Reports/DE0005227235-Q2-2010-EQ-D-00.pdf English: ...

Further information
2010 AFR
19.03.2010

Biotest AG: 2009 brings additional growth

2009 brings additional growth - Sales up by 14.1% to EUR440.2 million, EBIT improved by 4.2% - Important progress made in R&E projects - Expanded position as specialist for immunological and haematological therapies Dreieich, 19 March 2010. The Biotest Group presented its definitive figures for the financial year 2009 today. The supplier of plasma proteins and diagnostic products for ...

Further information
2010 CORPORATE
17.03.2010

Biotest AG: Monoclonal antibody BT-061 shows efficacy in the indication psoriasis

Monoclonal antibody BT-061 shows efficacy in the indication psoriasis  Final results of Phase I/IIa trial in chronic plaque psoriasis show long- lasting therapeutic effect after a single administration in the relevant dose levels  Good safety confirmed by comprehensive testing  First patients treated in a new phase II trial with repeated dosing Dreieich, 17 March 2010. Biotest ...

Further information
2010 CORPORATE
16.02.2010

Biotest AG: Biotest significantly increases sales, EBIT above the high level of last year

Biotest significantly increases sales, EBIT above the high level of last year Dreieich, 16 February 2010. According to preliminary and unaudited figures, the Biotest Group (Continued Business) recorded sales of EUR 440.2 million in financial year 2009, an increase of 14.1% compared to the previous year (EUR 385.9 million). Earnings before interest and tax (EBIT) are in the range of EUR 61 ...

Further information
2010 ADHOC
04.02.2010

Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that the following financial reports shall be disclosed: Report: Annual financial report Date of disclosure / German: March 19, 2010 German: http://irpages.equitystory.com/download/Companies/biotest/Annual%20Reports/Biotest_Einzelabschluss2009.pdf Report: Annual financial report of the group Date of disclosure / German: March 19, 2010 Date of disclosure / ...

Further information
2010 AFR
06.01.2010

Biotest AG: Sale of Medical Diagnostics business to Bio-Rad completed

Sale of Medical Diagnostics business to Bio-Rad completed - Transaction has been successfully closed today after clearance of merger control authorities was given - Biotest's Microbiology business in the US now with Biotest Microbiology Corp. Rockaway, NJ, USA Dreieich, 6. January 2010. All relevant European merger control authorities approved the sale of major parts of Biotest's Medical ...

Further information
2010 CORPORATE
07.12.2009

Biotest AG: Immunoconjugate BT-062 shows first data of clinical efficacy

Immunoconjugate BT-062 shows first data of clinical efficacy * Presentation of preliminary data of a multicenter Phase I Study in Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology * Further development in more intensive dosage programme Dreieich, 7 December 2009. At the Annual Meeting of the American Society of Hematology in New Orleans, Biotest presented ...

Further information
2009 CORPORATE
03.12.2009

Biotest AG: European Commission grants approval of Zutectra(R)

European Commission grants approval of Zutectra(R) * Worldwide the first ready-to-use Hepatitis B Immunoglobulin solution for subcutaneous administration * Marketing in Europe can start now Dreieich, 3. December 2009. The European Commission has granted marketing approval to Biotest for the hepatitis B immunoglobulin Zutectra(R) after the Committee for Medicinal Products for Human Use ...

Further information
2009 CORPORATE
05.11.2009

Biotest AG: Biotest increases sales and earnings

Biotest increases sales and earnings - Nine-month figures: sales increase by 12.0%, while EBIT grows by 3.0% - Forecast for the full year 2009 confirmed Dreieich, 5 November 2009. In the first nine months of 2009, the Biotest Group increased sales and earnings compared with the previous year's figures in the same period. Sales increased by 12.0% to EUR361.9 million (2008: EUR323.0 million). ...

Further information
2009 CORPORATE
23.10.2009

Biotest agrees to sell its Medical Diagnostics business to Bio-Rad Biotest AG:

Biotest agrees to sell its Medical Diagnostics business to Bio-Rad * Even stronger focus on plasma protein business and the clinical development of biotherapeutics * Transaction is expected to close in Q1 2010; purchase price amounts to EUR45 million Dreieich, 23 October 2009. Biotest AG announced today that it has signed an agreement to sell major parts of its Medical Diagnostics ...

Further information
2009 CORPORATE
23.10.2009

Biotest AG: Biotest agrees to sell its Medical Diagnostics business to Bio-Rad

Biotest agrees to sell its Medical Diagnostics business to Bio-Rad Dreieich, 23 October 2009. Biotest AG announced today that it has signed an agreement to sell major parts of its Medical Diagnostics segment to Bio-Rad Laboratories, Inc. (Hercules, CA/USA), a multinational manufacturer and distributor of life science research and clinical diagnostic products. The transaction is subject to ...

Further information
2009 ADHOC
20.10.2009

Biotest AG: Monoclonal antibody BT-061 shows efficacy in patients with rheumatoid arthritis

Monoclonal antibody BT-061 shows efficacy in patients with rheumatoid arthritis * Unblinded data from analysis of 40 patients in a clinical Phase II trial indicates efficacy and good tolerability * Positive response rates at week 9 (after 8-week treatment) in patients receiving treatment with BT-061 in combination with methotrexate (MTX) Dreieich, 20th October 2009. In the unblinded ...

Further information
2009 CORPORATE
30.09.2009

Biotest AG: Clinical development of BT-063 started

Clinical development of BT-063 started - Monoclonal antibody for the lead indication systemic lupus erythematosus - Phase I clinical trial with 24 healthy volunteers started - All three antibodies in the Biotest pipeline now in clinical development Dreieich, 30 September 2009. Biotest AG has achieved a further milestone in the development of monoclonal antibodies (mAb). The antibody BT-063 ...

Further information
2009 CORPORATE
28.09.2009

Biotest AG: Biotest AG receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for approval of Zutectra across the EU

Dreieich, 28 September 2009. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion for approval of Biotest's hepatitis B immunoglobulin Zutectra. The positive assessment is based on the comprehensive data available to the EMEA, which was reviewed as part of the centralised approval procedure. In the next step, this ...

Further information
2009 CORPORATE
12.08.2009

Biotest AG:Biotest remains successful

Biotest remains successful § Sales and EBIT in the first half of 2009 significantly increased compared to previous year's figures § Important progress made in R&D projects Dreieich, 12 August 2009. The Biotest Group once again reported profitable growth in the first half of 2009. The company which specialises in pharmaceuticals, biotherapeutics and diagnostics reported sales of ...

Further information
2009 CORPORATE
12.08.2009

Biotest AG: Ad-hoc RELEASE; Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

Dreieich, August 12, 2009. The Company is in discussions to sell its business division 'Medical Diagnostics', which essentially consists of the Biotest Medical Diagnostics GmbH in Dreieich and the Biotest Diagnostics Corporation in Rockaway/ USA. The discussions are getting more focussed now. Exclusive negotiations to sell the business division will be conducted with one particular party ...

Further information
2009 ADHOC
07.07.2009

Biotest AG: Further interim analyses confirm good clinical efficacy of the BT-061 monoclonal antibody.

Further interim analyses confirm good clinical efficacy of the BT-061 monoclonal antibody. - Marked improvement in symptoms even after short period of treatment - Over 240 individuals treated with BT-061 Dreieich, 7 July 2009. After the ongoing clinical development in the indication of psoriasis has provided evidence of the efficacy of the BT-061 monoclonal antibody, this has now also been ...

Further information
2009 CORPORATE
15.05.2009

Biotest AG: Successful Start into 2009

Successful Start into 2009 · Sales and EBIT significantly increased compared to the first quarter in the previous year · Operating basis broadened by expansion of capacity and additional approvals Dreieich, 15 May 2009. Financial year 2009 started well for Biotest Group. In the first quarter, the company, which specialises in pharmaceuticals, biotherapeutics and diagnostics, recorded ...

Further information
2009 CORPORATE
07.05.2009

Biotest AG: Annual General Meeting: Shareholders Approve Dividend of EUR 0,30 per Ordinary Share and EUR 0,36 per Preference Share

Annual General Meeting: Shareholders Approve Dividend of EUR 0,30 per Ordinary Share and EUR 0,36 per Preference Share Dreieich/ Frankfurt am Main, May 7, 2009 - Shareholders of Biotest AG with 79,11% of shareholder present, approved a dividend of EUR 0.30 per ordinary share for 2008 and a dividend of EUR 0.36 per preference share at the company's Annual General Meeting held today in ...

Further information
2009 CORPORATE
07.05.2009

Biotest AG: Press Release- Biotest AG: 'Biotest sales and EBIT growth in first quarter; extension of credit facility'

Press Release- Biotest AG: 'Biotest sales and EBIT growth in first quarter; extension of credit facility' - Q1 2009: Revenue Growth of 13% and EBIT increase of 8% - Extension of Credit facility Dreieich/ Frankfurt am Main, May 7, 2009 - In his speech at the Annual General Meeting today, the Chairman of the Management Board, Prof. Dr. Gregor Schulz announced sales and earnings before ...

Further information
2009 ADHOC
07.04.2009

Biotest AG: Expansion of product offering and capacity

Expansion of product offering and capacity - Immunoglobulin Hepactect(R) CP approved for additional European countries - Approval of a second immunoglobulin production plant - Annual production capacity doubled to four tonnes Dreieich, 7 April 2009. The Biotest Group has expanded the sales and marketing base for its plasma proteins business and increased the production capacity. Hepatitis B ...

Further information
2009 CORPORATE
11.03.2009

Biotest AG: Successful Financial Year 2008

Successful Financial Year 2008 - Sales up 29.6 % to EUR 423.0 million, with exceptional increase in EBIT - Internationalisation and R&D projects on schedule - Outlook 2009: 10% increase in sales, with EBIT on previous year's level Dreieich, 11 March 2009. The Biotest Group announced its final figures for 2008 today. The Pharmaceutical and Diagnostics group has recorded a 29.6% increase ...

Further information
2009 CORPORATE
11.02.2009

Biotest AG: Biotest acquires further plasmapheresis centre

Biotest acquires further plasmapheresis centre - Station in the USA with annual collection capacity of 40,000 litres - Number of centres operated by Biotest rises to 21 - Independence and resources secured through high level of self-sufficiency Dreieich, 11 February 2009. Biotest has acquired a further plasmapheresis centre in the USA. US subsidiary Biotest Pharmaceuticals Corporation ...

Further information
2009 CORPORATE
04.02.2009

Biotest AG: Biotest records significant growth in sales and earnings, Majority shareholder terminates discussion about shares' sale

Biotest records significant growth in sales and earnings, Majority shareholder terminates discussion about shares' sale Dreieich, 4 February 2009. According to preliminary and unaudited figures, the Biotest Group recorded sales of EUR 423 million in financial year 2008, representing an increase of 30% on the previous year (EUR 326.4 million). Earnings before interest and tax (EBIT) are in the ...

Further information
2009 ADHOC
03.02.2009

Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that the following financial reports shall be disclosed: Report: Annual financial report Date of disclosure / German: March 23, 2009 Date of disclosure / English: March 23, 2009 German: http://irpages.equitystory.com/download/Companies/biotest/Annual%20Reports/Biotest_Einzelabschluss2008.pdf English: Report: Annual financial report of the group Date of ...

Further information
2009 AFR
21.01.2009

Biotest AG: Cooperation secures additional plasma protein capacity

Cooperation secures additional plasma protein capacity - Biotest agrees increased utilisation of CAF-DCF fractionation capacity - Agreement to run for ten years - Annual Biotest capacity now rises to 1.4 million litres Dreieich, 21 January 2009. Biotest has considerably expanded its plasma fractionation capacity and broadened its basis for future growth by signing a further cooperation ...

Further information
2009 CORPORATE
12.01.2009

Biotest AG: Expansion of plasma protein product range

Expansion of plasma protein product range - Approval for Albiomin 5% and Albiomin 20% in European core markets - Preparation for use in acute medicine - Possibility of more efficient use of plasma as a raw material Dreieich, 12 January 2009. Biotest has been granted approval by the responsible authorities for the albumin preparations Albiomin 5% and Albiomin 20% under the European Mutual ...

Further information
2009 CORPORATE
15.12.2008

Biotest AG: Enhanced property rights for BT-062

Enhanced property rights for BT-062 - European Commission grants Orphan Drug designation to the monoclonal antibody - Designation ensures ten years’ market exclusivity in the EU from approval of the drug for the treatment of multiple myeloma - Phase I clinical trials underway Dreieich, 15 December 2008. The European Commission has granted Biotest’s monoclonal antibody BT-062 Orphan ...

Further information
2008 CORPORATE
10.12.2008

Biotest AG: European approval for Haemonine®

European approval for Haemonine® - Coagulation factor IX approved in the most important European markets - Preparation for the treatment of type B haemophilia completes product spectrum - Possibility of more efficient use of plasma as a raw material Dreieich, 10 December 2008. Biotest has taken another step forward in the continued development of its plasma protein business. The ...

Further information
2008 CORPORATE
10.12.2008

Biotest AG: Biotest expands plasma recovery capacities

Biotest expands plasma recovery capacities - New plasmapheresis centre in Nordhausen - Number of stations operated by Biotest rises to 19 worldwide - High degree of self-sufficiency makes Biotest more independent of global market Dreieich, 10. December 2008. Biotest AG has expanded its own capacities for obtaining raw material for its fast-growing plasma protein business. The company ...

Further information
2008 CORPORATE
28.10.2008

Biotest AG: Majority shareholder of Biotest AG in discussions about selling shares

Biotest AG: Majority shareholder of Biotest AG in discussions about selling shares Dreieich, the 28th of October 2008: The majority shareholder of Biotest AG, OGEL GmbH, informed the management board that OGEL GmbH is in discussions to dispose of parts of its share package. OGEL GmbH wishes to negotiate a transaction in close coordination with the management board of the company. According to ...

Further information
2008 ADHOC
17.10.2008

Biotest AG: Biotest: proceeding successfully

Biotest: proceeding successfully · Sales and EBIT for the first nine months considerably higher than the figures for the previous year · Board of Management confirms targets for the year as a whole · Financing secured through long-term credit lines Dreieich, 17 October 2008. Financial year 2008 is continuing to proceed extremely successfully for the Biotest Group. According to ...

Further information
2008 CORPORATE
22.09.2008

Biotest AG: Biotest: Promising start of clinical trial with BT062

Biotest: Promising start of clinical trial with BT062 - Monoclonal antibody was generally well tolerated at the first dose level - Clinical study in indication multiple myeloma can proceed as planned - High medical need Dreieich, September 22nd, 2008. Treatment of first patients with BT-062 commenced in the US. The drug – which is developed in the indication of multiple myeloma - was ...

Further information
2008 CORPORATE
08.09.2008

Biotest AG: Biotest: monoclonal antibody BT-061 shows clear indications of efficacy in the treatment of Psoriasis

Biotest: monoclonal antibody BT-061 shows clear indications of efficacy in the treatment of Psoriasis - First analysis of clinical Phase I/IIa trial - Clear improvement of symptoms already at low dosages - Development in Rheumatoid Arthritis according to plan Dreieich, 08 September 2008. Biotest has achieved another major milestone in its biotherapeutic research and development projects. ...

Further information
2008 CORPORATE
18.08.2008

Biotest AG: Biotest: US approval increases potential of diagnostic business

Biotest: US approval increases potential of diagnostic business · FDA authorises marketing of manual reagents for blood group typing · Biotest consequently consolidates its position in the world’s largest and most attractive market · Objective: annual sales of around US$50 million within five years Dreieich, 18 August 2008. Biotest has made significant progress in ...

Further information
2008 CORPORATE
07.08.2008

Biotest AG: Biotest strengthens self-sufficiency in Plasma Proteins

Biotest strengthens self-sufficiency in Plasma Proteins · Opening of new plasmapheresis centres in the USA, Germany and Hungary · Consequently, Biotest will operate 20 of its own centres worldwide this year · Self-sufficiency rate target of 50% Dreieich, 7 August 2008. Biotest is significantly expanding its capacities for obtaining blood plasma, the raw material used in the production ...

Further information
2008 CORPORATE
29.07.2008

Biotest AG: Biotest awarded patent protection in the USA

Biotest awarded patent protection in the USA · Patent prosecution for BT-061 successfully completed by US authorities · Decision confirms innovative character of the monoclonal antibody · Comprehensive protection against generic drugs Dreieich, 29 July 2008. Biotest’s BT-061 monoclonal antibody has been recognised as an innovative development and awarded comprehensive patent protection in ...

Further information
2008 CORPORATE
18.07.2008

Biotest AG: strong first half year, profit target raised

Biotest: strong first half year, profit target raised Dreieich, 18 July 2008. According to preliminary figures, in the first half of 2008 Biotest achieved sales of €210.9 million, which represents a 33% increase year-on-year (€158.4 million). Earnings before interest and tax (EBIT) rose 52% to €27.6 million (2007: €18.2 million). At €14.4 million, Biotest’s earnings after tax were up 53% in ...

Further information
2008 ADHOC
27.05.2008

Biotest AG: Forecast for turnover and profit raised

Biotest: Forecast for turnover and profit raised Dreieich, 27 May 2008. The Managing Board of Biotest AG raised the company's forecast for turnover and profit in the current year. The Management now expects sales of EUR 420 million in 2008, following EUR 326.4 million in the previous year. Until now the target had been EUR 400 million. Earnings before interest and tax (EBIT) are expected to ...

Further information
2008 ADHOC
27.05.2008

Biotest AG: Payout of dividends increased, forecast improved

Biotest: Payout of dividends increased, forecast improved · General meeting finalises fifth dividend increase in a row · Managing Board raises forecast considerably for the current year · Goals for 2008: Turnover of EUR 420 million, 20% EBIT growth Dreieich, May 27, 2008. At today's general meeting of Biotest AG in Frankfurt/Main, shareholders approved of the suggestion by the Managing Board ...

Further information
2008 CORPORATE
16.05.2008

Biotest AG: Successful start into the Year 2008

Biotest AG: Successful Start into 2008 - Q1 Sales of EUR 105.5 million: 39% higher than in the same period of last year - Operating profit (EBIT) increased to EUR 13.3 million compared to EUR 8 million in Q1 2007 Dreieich, 16 May 2008. Financial year 2008 started well for Biotest Group. In the first quarter, the company, which specialises in pharmaceuticals, biotherapeutics and ...

Further information
2008 CORPORATE
05.05.2008

Biotest AG: research into additional indications for monoclonal antibody BT-061

Biotest: research into additional indications for monoclonal antibody BT-061 - Research cooperation agreed with the University of Mainz for BT-061 - Biotest’s industrial property rights extended - Rheumatoid arthritis and psoriasis trials are progressing as planned Dreieich, 5 May 2008. The Biotest Group and Johannes Gutenberg University in Mainz have concluded an agreement which grants ...

Further information
2008 CORPORATE
14.04.2008

Biotest AG: European approvals expand the market potential for plasma proteins

Biotest: European approvals expand the market potential for plasma proteins · Factor VIII product Haemoctin® and immunoglobulin Hepatect® approved for use in additional countries · Synergies generated for sales and marketing · Further European approvals expected in the current year Dreieich, 14 April 2008. The Biotest Group has achieved further milestones to promote the ...

Further information
2008 CORPORATE
07.04.2008

Biotest AG: Biotest: Successful launch of plasma protein business in the USA

Biotest: Successful launch of plasma protein business in the USA · Work to integrate the activities acquired from Nabi Biologics in December 2007 is on schedule · Preparations for a capacity expansion have been completed · Sales and income in the first quarter match expectations Dreieich, 7 April 2008. The Biotest Group has successfully completed its first quarter as a plasma protein ...

Further information
2008 CORPORATE
11.03.2008

Biotest AG: Biotest achieves major milestones in the development of biotherapeutics

Biotest achieves major milestones in the development of biotherapeutics · Orphan drug designation granted for monoclonal antibody, BT-062, in the USA · Up to seven years’ market exclusivity from approval · Clinical testing for indication multiple myeloma anticipated to start in the first six months of 2008 Dreieich, 11 March 2008. Biotest has achieved some further major milestones in ...

Further information
2008 CORPORATE
11.03.2008

Biotest AG: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution

Biotest AG hereby announces that the following financial reports shall be disclosed: Report: Annual financial report Date of disclosure / German: March 28, 2008 Date of disclosure / English: March 28, 2008 ...

Further information
2008 AFR
22.02.2008

Biotest AG: 2007 a very successful year for Biotest

2007 a very successful year for Biotest · Sharp increases in sales and earnings · Plasma proteins reach a new level · Strategic restructuring of Diagnostics continues · Biotherapeutics: clinical development of BT-061 yields positive data Dreieich, 22 February 2008. The Biotest Group recorded a marked increase in sales and earnings in financial year 2007. According to preliminary figures, for ...

Further information
2008 CORPORATE
22.02.2008

Biotest AG: Biotest marked increase in sales and earnings recorded in 2007

Biotest marked increase in sales and earnings recorded in 2007 Dreieich, 22 February 2008. The Biotest Group recorded sales totalling EUR 326.4 million in financial year 2007, according to preliminary figures, which is 15.8% up on the figure for the previous year (EUR 281.9 million). Earnings before interest and tax (EBIT) rose by 22.6% to EUR 38.5 million (2006: EUR 31.4 million). The EBIT ...

Further information
2008 ADHOC
05.12.2007

Biotest AG:Biotest successfully completes acquisition of Nabi Biologics assets

Biotest successfully completes acquisition of Nabi Biologics assets · Reduced net borrowings due to favourable dollar exchange rate · Management team for US plasma protein business determined · Sustainable structure for European pharmaceutical activities achieved Boca Raton/Dreieich, 5 December 2007. Biotest AG has successfully completed the first step in the acquisition of the plasma ...

Further information
2007 CORPORATE
09.11.2007

Biotest AG: Nabi shareholders approve sale of Biologics Business Unit to Biotest

Nabi shareholders approve sale of Biologics Business Unit to Biotest · Transfer of almost 500 employees planned for December · New syndicated loan agreement signed Boca Raton / Dreieich, 9 November 2007. At the Annual Shareholders’ Meeting held yesterday in Maryland, the shareholders of Nabi Biopharmaceuticals Corp., Boca Raton (Florida, USA), approved the sale of the Biologics Business Unit ...

Further information
2007 CORPORATE
05.11.2007

Biotest AG: Biotest: plasmapheresis centre in Dortmund opens

Biotest: plasmapheresis centre in Dortmund opens · Seventh centre operated by the Group to obtain blood plasma in Germany · Following the acquisition of Nabi, 17 collection stations worldwide · Operation of own donor centres secures long-term supply of high quality plasma Dreieich, 5.November 2007. PlasmaService Europe, a subsidiary of Biotest AG, Dreieich, has today opened a new ...

Further information
2007 CORPORATE
21.09.2007

Biotest AG:Biotest successfully concludes 10% capital increase

Biotest successfully concludes 10% capital increase Dreieich, 21 September 2007. Biotest AG, Dreieich has increased its share capital by 10%. The 599,567 new ordinary shares and 466,666 new preference shares were placed through an accelerated bookbuilding process and under the exclusion of subscription rights among institutional shareholders. With an issue price of EUR 32.70 per ordinary ...

Further information
2007 ADHOC
11.09.2007

Biotest AG:Biotest AG acquires plasma protein business unit from Nabi Biopharmaceuticals Corp.

Biotest AG acquires plasma protein business unit from Nabi Biopharmaceuticals Corp. · Acquisition of FDA-certified pharmaceutical production facilities and nine plasmapheresis centres · Immediate strong presence in the USA with hyperimmunoglobulins and plasma raw material · Strong sales and earnings growth expected in the medium term based on new market approvals of immunoglobulins · ...

Further information
2007 CORPORATE
11.09.2007

Biotest AG:Biotest AG acquires plasma protein unit from Nabi Biopharmaceuticals Corp.

Biotest AG acquires plasma protein unit from Nabi Biopharmaceuticals Corp. Dreieich, 11 September 2007. Biotest AG, Dreieich has acquired the Biologics business unit ('Nabi Biologics') from Nabi Biopharmaceuticals Corp., Boca Raton (Florida, USA) in which the company’s plasma protein operations are pooled, including the company’s headquarters. The purchase price stands at USD 185 million ...

Further information
2007 ADHOC
10.08.2007

Biotest AG: Biotest remains on course for growth

Biotest remains on course for growth · Clear rise in sales and earnings in the first half of 2007 · Sustained dynamic trend in plasma proteins · Measure to increase earnings in the Diagnostic segment · Key milestones achieved in R&D projects Dreieich, 10 August 2007. The Biotest Group today published its half-year report as of 30 June 2007. With an increase in sales of 15.5% to EUR ...

Further information
2007 CORPORATE
01.08.2007

Biotest AG:Biotest and Abbott cooperate on a clinical trial for the expansion of the indication of Cytotect®

Biotest and Abbott cooperate on a clinical trial for the expansion of the indication of Cytotect® · Trial with more than 20,000 participants for the approval of the immunoglobulin in the indication connatal CMV infection · Abbott acts as diagnostics partner · Approval would result in a substantial increase in market potential for Biotest. Dreieich, 1 August 2007. Biotest AG, Dreieich, has ...

Further information
2007 CORPORATE
19.07.2007

Biotest AG: Biotest significantly increases sales and earnings target for 2007

Dreieich, 19 July 2007. According to provisional figures, the Biotest Group recorded sales totalling EUR 158.4 million in the first six months of 2007, outperforming the previous year's figure (EUR 137.2 million) by 15.5%. Earnings before interest and tax (EBIT) amounted to EUR 18.2 million, which is 27.3% up on the comparative figure of EUR 14.3 million in 2006. The Pharmaceutical segment ...

Further information
2007 ADHOC
16.07.2007

Biotest AG: New clinical results increase market potential of Cytotect®

New clinical results increase market potential of Cytotect® · Scientific study: administration of CMV- immunoglobulins reduces risk of tumour diseases following transplants · Data of more than 40,000 patients analysed · Transplant doctors discuss practice consequences Dreieich, 16 July 2007. The indication range of Biotest's immunoglobulin, Cytotect®, may be expanded. An article published ...

Further information
2007 CORPORATE
25.06.2007

Biotest AG: Biotest achieves further milestones in its monoclonal antibody development

Biotest achieves further milestones in its monoclonal antibody development · Phase I clinical trial confirms good tolerability profile of BT-061. · Start of production for the clinical testing of BT-062. Dreieich, 25 June 2007. The monoclonal antibody BT-061, developed by Biotest AG, Dreieich, has demonstrated a very good tolerability profile in a recently completed Phase I clinical study. ...

Further information
2007 CORPORATE
15.06.2007

Biotest receives go-ahead to export culture media to the USA

Biotest receives go-ahead to export culture media to the USA · Affiliate heipha is granted certification for the export of culture media · Focus on hygiene monitoring in the pharmaceutical industry · Biotest Diagnostics Corporation launched sales this week Dreieich/Eppelheim/Denville, 15 June 2007. The Biotest Group has taken a key step forward in the expansion of its diagnostic business in ...

Further information
2007 CORPORATE
03.05.2007

Biotest AG: successful start to 2007

Biotest AG: successful start to 2007 - Q1 sales 12 % higher than in the same period of the previous year - With a 16 % rise, earnings grow faster than sales - Measures have been introduced to improve earnings situation in the diagnostic segment Dreieich, 3 May 2007. Financial year 2007 has started well for Biotest Group. In the first quarter, the company, which specialises in ...

Further information
2007 CORPORATE
13.03.2007

Biotest AG: Board of Management and Supervisory Board propose 82% dividend increase

Biotest AG: Board of Management and Supervisory Board propose 82% dividend increase - Planned dividend of EUR 0.24 per ordinary share and EUR 0.30 per preference share - Total distribution payment up from almost EUR 1.6 million to more than EUR 2.8 million - Contract of the Chairman of the Board, Professor Dr. Gregor Schulz, extended by five years Dreieich, 13 March 2007. The Board of ...

Further information
2007 CORPORATE
14.02.2007

Biotest AG: 2006 financial year considerably better than expected

2006 financial year considerably better than expected - Sales up 18.7% compared with the previous year, with 24.1% rise in EBIT - Continuous strong growth for plasma proteins - New strategic focus for Diagnostic segment - Further milestones achieved in monoclonal antibody development Dreieich, 14 February 2007. In financial year 2006, the sales and results of the Biotest Group were both ...

Further information
2007 CORPORATE
14.02.2007

Biotest AG: Increase in sales and earnings in financial year 2006 higher than expected

Increase in sales and earnings in financial year 2006 higher than expected Dreieich, 14 February 2007. According to unaudited figures, Biotest Group sales were 18.7% up on the previous year (EUR 237.6 million) to EUR 281.9 million. At EUR 31.4 million, earnings before interest and taxes (EBIT) were 24.1% higher than in financial year 2005 (EUR 25.3 million), with an improvement in profit ...

Further information
2007 ADHOC
04.01.2007

Biotest AG: Orphan drug status for Cytotect® in the USA

The decision of the US approval authority (FDA) ensures seven years' of exclusive market access to the treatment of cytomegalovirus infections in pregnancy. Biotest estimates that the additional market potential for this new indication will amount to EUR 70 million per year. Dreieich, 5 January 2007. The US Food and Drug Administration (FDA) has granted orphan drug status to Biotest's ...

Further information
2007 CORPORATE
21.12.2006

Biotest AG: Major milestones achieved in the development of monoclonal antibodies. – Commencement of clinical development of BT-061.

Major milestones achieved in the development of monoclonal antibodies. – Commencement of clinical development of BT-061. Approval by regulatory authority to begin clinical development with BT-061. Impressive efficacy of BT-062 in several animal models for Multiple Myeloma - manufacturing agreement with CMC Biopharmaceuticals to provide antibody for clinical trials. Dreieich, December 21, ...

Further information
2006 CORPORATE
14.11.2006

Biotest AG: Biotest confirms sales and earnings target following good third quarter

Biotest confirms sales and earnings target following good third quarter Sales up 17.5% after nine months, EBIT up 19% year-on-year / Strong growth in plasma protein business / Focus in Diagnostics on immunology and microbiology / According to positive new data, clinical trials imminent in Biotherapeutics / Orphan drug status approved for Cytotect® Dreieich, 14 November 2006. Biotest AG, ...

Further information
2006 CORPORATE
02.11.2006

Biotest AG:Biotest obtained approval for improved Hepatect® product in six European countries

Marketing of the preparation for hepatitis prophylaxis is planned for this year. Modern manufacturing procedures will facilitate a higher degree of product purity and optimum use of raw materials. Dreieich, 2 November 2006. The immunglobulin Hepatect® manufactured by Biotest using modern filter aid procedures, can now be marketed in six European countries. The responsible authorities in ...

Further information
2006 CORPORATE
20.10.2006

Biotest AG: Olympus and Biotest redefine distribution relationship for Tango® systems

Olympus and Biotest redefine distribution relationship for Tango® systems Center Valley, PA / Dreieich, 20 October 2006. Olympus America Inc. and Biotest AG of Germany have redefined the agreement under which Biotest’s TANGO® Automated Blood Bank systems will be sold, serviced and supported throughout the U.S. Under the new relationship, Biotest will market TANGO directly to American ...

Further information
2006 CORPORATE
20.10.2006

Biotest AG: Biotest Diagnostics Corporation Announces Appointment of Vice President, Transfusion Diagnostics

Biotest Diagnostics Corporation Announces Appointment of Vice President, Transfusion Diagnostics Denville, NJ / Dreieich, 20 October 2006. Biotest Diagnostics Corporation (BDC), a subsidiary of Biotest AG, a worldwide supplier of manual and automated solutions to the blood bank industry, announces the appointment of Candace K. Williams to the newly created position of Vice President ...

Further information
2006 CORPORATE
20.10.2006

Biotest AG: Biotest announces important Milestone for Full Line of Manual Blood Bank Reagents

Biotest announces important Milestone for Full Line of Manual Blood Bank Reagents Denville, NJ / Dreieich, 20 October 2006. Biotest Diagnostics Corporation (BDC), subsidiary of Biotest AG, a worldwide supplier of manual and automated solutions to the blood bank industry, announced today that it has made Biologic License Applications and 510(k) premarket notification submissions to the U.S. ...

Further information
2006 CORPORATE
20.10.2006

Biotest AG: New Automated Assays for TANGO® Automated Blood Bank Systems under Food and Drug Administration Review

New Automated Assays for TANGO® Automated Blood Bank Systems under Food and Drug Administration Review Denville, NJ, 20 October 2006. Biotest Diagnostics Corporation (BDC), subsidiary of Biotest AG, a worldwide supplier of manual and automated solutions to the blood bank industry, announced today that it made Biologic License Applications and 510(k) premarket notifications to the U. S. ...

Further information
2006 CORPORATE
28.09.2006

Biotest AG: EMEA Committee in favour of Orphan Drug status for Cytotect®

EMEA Committee in favour of Orphan Drug status for Cytotect® Large market potential for treatment of cytomegalovirus infections during pregnancy / Europe-wide authorisation study to begin at the start of 2007 / Good chances of Orphan Drug status in the USA too / Positive reactions from Gynaecologists and private health insurers Dreieich, 28 September 2006. The hyperimmunoglobuline, ...

Further information
2006 CORPORATE
14.08.2006

Biotest AG: Continuing growth

Biotest AG: Continuing growth · First half year of 2006: Sales rise by 19.1% to €137.2 million, an even more marked increase in operating profit than in sales · Success from coagulation agents and immunoglobulins · Contract with ImmunoGen a key milestone in the development of biotherapeutics Dreieich, 14 August 2006. In the first half-year of 2006, the Biotest Group achieved sales of €137.2 ...

Further information
2006 CORPORATE
11.07.2006

Biotest secures exclusive rights to ImmunoGen’s world leading cytotoxic agent technologyest AG:

Biotest secures exclusive rights to ImmunoGen’s world leading cytotoxic agent technology Collaboration and licensing agreement with ImmunoGen secures future global sales of cancer therapy based on the BT-062 antibody. Option for joint development in the USA – license payments dependent on milestones Cambridge, MA/Dreieich, July 11, 2006. Biotest AG, Dreieich, has secured, via a ...

Further information
2006 CORPORATE
11.05.2006

Biotest AG:Good start to 2006 – a year of growth: Group sales up by 21%, overproportional growth recorded in earnings

Good start to 2006 – a year of growth: Group sales up by 21%, overproportional growth recorded in earnings Strong increases in immunoglobulins and coagulative agents – sales and earnings target for financial year 2006 as a whole confirmed Dreieich/Frankfurt/Main, 11 May 2006. Biotest AG, Dreieich, achieved Group sales of € 67.5 million in the first quarter of 2006, which represents ...

Further information
2006 CORPORATE
11.05.2006

Biotest AG: Stock option programme fails to achieve required majority

Biotest AG: Stock option programme fails to achieve required majority from preferred shareholders Dreieich/Frankfurt/Main, 11 May 2006. With 83.46% of shareholders present, the Annual General Meeting of Biotest AG, Dreieich, today approved by a large majority (94.64%) the creation of conditional capital amounting to € 0.98 million to secure subscription rights under a company stock ...

Further information
2006 CORPORATE
22.03.2006

Biotest AG:Supervisory Board announces early extension of Dr. Michael Ramroth’s (CFO), contract by five years

Supervisory Board announces early extension of Dr. Michael Ramroth’s (CFO), contract by five years Dreieich, 21 March 2006. The Supervisory Board of Biotest AG, Dreieich, extended the contract of Dr. Michael Ramroth (44), which was originally due to expire in February 2007, by a further five years. Dr. Ramroth is responsible for Finance and Central Services (including Legal and ...

Further information
2006 CORPORATE
22.03.2006

Biotest AG:“Focused research, global growth”: Biotest increases its market share worldwide and announces ambitious targets for 2006

“Focused research, global growth”: Biotest increases its market share worldwide and announces ambitious targets for 2006 Intratect sales to treble by 2007 – high level of demand for immunoglobulins results in planned capacity expansion to 4,000 kg – aim is to achieve orphan drug status for Cytotect® in the European Union Dreieich, Frankfurt/Main, 21 March 2006. Biotest AG, ...

Further information
2006 CORPORATE